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9Chapter 1
Telomerase-dependent Cell Cycle Regulation 
Requires NOL1
10
1. Abstract
Telomerase is a ribonucleoprotein enzyme that plays a critical role in the maintenance of 
telomere repeats in most eukaryotic organisms. Although overexpression of telomerase in 
normal human somatic cells is sufficient to overcome replicative senescence and extend a 
lifespan, the ability of telomerase to promote tumorigenesis could require additional activities 
that are independent of its role in telomere extension. Here we identify NOL1 (proliferation-
associated nuclear antigen 120) as a TERC-binding protein, which is found in association with 
catalytically active telomerase. We show that NOL1 binds to cyclin D1 promoter at the TCF 
binding element and activates its transcription. Moreover, telomerase further enhances 
expression of cyclin D1 gene by interacting with NOL1 and recruitment to the cyclin D1 
promoter, demonstrating a role of telomerase as a modulator of NOL1-dependent transcription 
in human cancer cells. These data suggest that NOL1 could represent a novel mechanism by 
which telomerase promotes the prolonged expression of growth-promoting genes critical for 
the maintenance of tumor survival and cell proliferation. (Chi and Delgado-Olguin 2013)
These data suggest that a functional interplay between NOL1 and telomerase plays a critical 
role in bypassing checkpoint signaling pathways and maintaining cell proliferation capacity, 
essential properties of telomerase required for cancer progression. 
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2. Introduction
Telomeres, the highly specialized nucleoprotein complexes located at the ends of eukaryotic 
chromosomes, are essential for maintenance of chromosome stability and genome integrity 
(Blackburn, 2001; Smogorzewska and de Lange, 2004). Telomeric DNA is tightly associated 
with the six-subunit protein complex shelterin which is composed of TRF1,TRF2, TIN2, TPP1, 
POT1, RAP1 and prevents chromosomal ends from being recognized as DNA damage (Liu et 
al., 2004; de Lange 2005; Palm and de Lange 2008; Sfeir and de Lange 2012). TRF1 and 
TRF2 directly bind to telomeric DNA containing myb DNA-binding domain and an internal 
TRFH homodimerization domain (de Lange 2009). Loss of TRF2 leads to cell cycle arrest and 
activation of ATM kinase at telomeres. TINF2 links TRF1 and TRF2, and it also binds to 
TPP1 that interacts with 3’ single-stranded overhang binding protein POT1. Depletion of 
POT1 induces phosphorylation of ATR target Chk1 (de Lange 2007). In the absence of a 
telomere maintenance pathway, most human somatic cells show a progressive loss of 
telomeric DNA with each round of cell division due to the end replication problem (Lingner et 
al., 1995; Blasco et al., 1997). The maintenance of telomere repeats in most eukaryotic 
organisms requires telomerase, which adds telomere repeats onto the 3’ ends of linear 
chromosomes by reverse transcription (Autexier and Lue 2006; Bianchi and Shore 2008). 
Human telomerase consists of telomerase reverse transcriptase (hTERT), telomerase RNA 
component (TERC), and several additional proteins including dyskerin, TCAB1, pontin, and 
reptin (Egan and Collins 2012; Venteicher et al., 2009; Venteicher et al., 2008). Telomerase 
expression is very low in most human somatic cells but upregulated in many human cancer 
cells and stem cells. Thus, telomerase plays critical roles in continued cell proliferation and 
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tumorigenesis by maintaining telomere integrity and homeostasis (Kim et al., 1994; Bodnar et 
al., 1998; Hahn et al., 1999).
Although overexpression of telomerase is sufficient to overcome replicative senescence 
(Bodnar et al., 1998), recent studies have revealed that besides its reverse transcriptase activity, 
telomerase has the noncanonical functions, which contribute to cancer development and 
progression (Stewart et al., 2002; Li and Tergaonkar, 2014). Ectopic expression of telomerase 
in human mammary epithelial cells resulted in enhanced expression of growth-promoting 
genes (Smith et al., 2003). Transgenic induction of TERT in mouse skin epithelium was shown 
to cause proliferation of quiescent stem cells (Sarin et al., 2005). Intriguingly, this function for 
TERT is independent of reverse transcriptase activity and of TERC (Choi et al., 2008). 
Furthermore, it has been reported that TERT directly interacts with BRG1 and activates 
Wnt/β-catenin-dependent genes such as cyclin D1 and c-Myc (Park et al., 2009). Although 
these data provide evidence to the nontelomeric functions of telomerase, the proposed 
noncanonical role of TERT in Wnt/β-catenin signaling cascade has been controversial. Several 
recent studies have reported a lack of physical association of hTERT with BRG1 or β-catenin 
(Listerman et al., 2014) as well as no apparent effect of TERT deficiency on phenotypes 
associated with Wnt signaling in TERT knockout mice (Strong et al., 2011). These findings 
suggest that hTERT may enhance the expression of growth-promoting genes, but this event 
may not be solely promoted by Wnt signaling. Indeed, hTERT has been reported to bind to 
NF-κB p65 subunit and regulate NF-κB-dependent gene expression by recruitment to specific 
target promoters (Ghosh et al., 2012). In addition, TERT forms a complex with RMRP to act 
as an RNA-dependent RNA polymerase (RDRP) (Maida, Y. et al., 2009). TERT-RMRP-RDRP 
complex produces RMRP-derived double-stranded RNAs (dsRNAs) that are further processed 
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into small interfering RNAs (siRNAs), which in turn regulate gene expression. As telomerase 
has regulatory roles in the expression of genes in cancer development and progression, a better
understanding of biochemical properties of telomerase could provide improved therapeautic
strategies in cancer treatment.
Since the large size of active human telomerase suggests the existence of additional 
components, we performed a large scale affinity purification to identify proteins that interact 
with telomerase. Here we identify NOL1 (proliferation-associated nucleolar antigen p120) as a 
TERC-binding protein. NOL1 was identified as a RNA-binding and nucleolar-specific protein, 
which is highly expressed in the majority of human malignant tumor cells but not detectable in 
normal resting cells (Ochs et al., 1988; Jhiang et al., 1990; Fonagy et al., 1992; Fonagy et al., 
1993). NOL1 is expressed early in the G1 phase and reaches its peak during early S phase, 
suggesting it may be involved in the regulation of cell cycle. Although NOL1 has been 
implicated as a tumor cell marker (Gorczyca et al., 1992), the molecular mechanism by which 
NOL1 contributes to tumorigenesis is poorly understood. In this work, we investigated a role 
of NOL1 and demonstrated that it binds to cyclin D1 promoter at the TCF binding element and 
activates its transcription. Furthermore, we show that telomerase associates with NOL1 via 
TERC and localizes to the cyclin D1 promoter in a NOL1-dependent manner, demonstrating a 
regulatory role of telomerase as a transcriptional modulator in human cancer cells. These data 
provides further insight to the noncanonical functions of telomerase and suggest potential 
intervention for telomerase-targeted cancer therapy.
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3. Materials and methods
Cell culture
Human cervical carcinoma HeLa S3 cells and human embryonic kidney 293cells were grown 
in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum with 100 units/mL 
penicillin, and 100 μg/mL streptomycin in 5% CO2 at 37 °C. Human osteosarcoma U2-OS 
cells were grown in McCoy’s modified medium with10% fetal bovine serum, 100 units/mL 
penicillin, and 100 μg/mL streptomycin in 5% CO2 at 37 °C.
Constructs 
The Nol1 expression vectors were constructed into pcDNA 3.1 V5/His or pCMV 3X flag. The 
human Cyclin D1 promoter luciferase plasmids (originally obtained from Richard Pestell) 
were subcloned into pGL4.20 puro -luc (promega).
Direct telomerase activity assays. 
Telomerase was immunopurified from cell extracts using the indicated antibodies. The 
reaction mixture (50 μl) contained TRAP reaction buffer (300 mM Tris-HCl, pH 8.3, 960 mM 
KCl, 23 mM MgCl2, 7.5 mM EDTA, pH 8.0, 0.05% Tween-20), 0.1 μM HTS primer, 0.1 mM 
dNTP with immunopurified telomerase complex on beads. Reactions were performed at 37°C 
for 20min and stopped by heat inactivation at 75°C. TRAP reaction samples were amplified by 
PCR. PCR was performed using the HTS primer and HACX primer for 30 cycles 
(denaturation at 94°C for 30 s, annealing at 62°C for 30 s, and extension at 72°C for 30 s). As 
an internal telomerase assay standard, NT and TSNT primers were added to the PCR mixture 
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as described previously. The amplified samples were loaded onto a 12% polyacrylamide non-
denaturing gel for electrophoresis. After electrophoresis, the gel was stained with SYBR 
Green (Molecular Probes). The signal intensity was quantified with a LAS-4000 PLUS Image 
analyzer (Fuji Photo Film). 
Transient transfection, immunoprecipitation and immunoblot.
HEK293 cells were transfected with following constructs using Lipofectamine 2000 according 
to the manufacturer's instruction(invitrogen). 24 hours after transfection, the cells were 
harvested.
For immunoblotting, whole-cell lysates were prepared using lysis buffer (0.5% NP-40, 0.5% 
Triton-X100, 150mM NaCl, 2mM EDTA(pH 8.0), 50mM Tris-HCl (pH7.5), 10% glycerol, 
and Proteinase inhibitor cocktail (Roche)) for 15 min at 4°C, followed by centrifugation 
(16,000 x g, 10 min). Supernatant fractions were denatured with 5X SDS sample buffer at 
98°C for 7 min, seperated by SDS–PAGE and transferred onto PVDF membrane. For 
immunoblot blocking, 5% skim milk in TBS-T (25mM Tris-HCl, pH 8.0, 125mM NaCl, 0.5% 
Tween-20) was used and primary antibodies were incubated overnight at 4°C. And then, 
membranes were washed 3 times in TBS-T, incubated for 1 hr in secondary 
antibody(Genedepot), washed 3 times and developed with ECL (Santa Cruz) solution. For 
immunoprecipitation, the cells were lysed with lysis buffer for 15 min at 4°C, followed by 
spinning at 16,000 x g for 10 min. The cell lysates were pre-cleared with protein A sepharose 
(GE Healthcare) for 30min. After spinning down, the supernatant was transferred into fresh 
tubes and incubated with antibodies at 4°C overnight. Subsequently, 40 μl of protein A 
sepharose was added and incubated for 1 h. Immunoprecipitates were washed 3times with 
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lysis buffer, then eluted by boiling in loading buffer and analysed by immunoblotting. Primary 
antibodies were used : anti-Flag(M2, sigma), v5(invitrogen), Nol1(Novus Biologicals), 
cyclinD1 (abcam), cyclin B1(SantaCruz), c-MYC(SantaCruz), TCAB1 (abcam), dyskerin 
(SantaCruz), TERT (Rockland), α-tubulin (SantaCruz), TRF1 (Santa Cruz), TRF2 (Cell 
signaling), RAP1 (Bethyl laboratory), POT1 (abcam), TPP1 (abcam), TIN2 (abcam), p53 
(SantaCruz), p21 (SantaCruz), Bcl-2 (SantaCruz), Bax (SantaCruz), Cleaved caspase-3 (Cell 
signaling).
Dual Luciferase assay
24 hrs after transfection, the cells were harvested. Firefly and Renilla luciferase activities were 
measured with Victor X5 multi plate reader using a dual luciferase kit (Promega, Madison, 
WI). The firefly luciferase data for each sample were normalized based on transfection 
efficiency as measured by Renilla luciferase activity. Each experiment was performed in 
triplicate and repeated at least three times.
Stable cell line generation using retroviral expressing vector. 
Phoenix cultures were grown in DMEM/10% bovine growth serum/100 units/mL penicillin, 
and 100 μg/mL streptomycin. Retroviruses were generated from Pheonix cells by transfecting 
the retroviral shRNA plasmids by Lipofectamine 2000 (invitrogen). To generate stable cell 
lines, HeLa S3 cells were transduced with shRNA constructs in the pSUPER.retro.puro vector 
(Oligogene), selected with 1μg/ml puromycin (GIBCO) for 2 weeks. For shRNA vectors, 
hairpin sequences were: 
sh-NOL1 A 5’-
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gatccccGCGTTGCTGCCCATTGAAATTttcaagagaAATTTCAATGGGCAGCAACGCttttta -
3’; 
sh-NOL1 B 5’-
gatccccGGACGATGCTGATACGGTATTttcaagagaAATACCGTATCAGCATCGTCCttttta -3’; 
sh-TERT A 5’-
gatccccGGGAATTTGGAGTGACCAATTttcaagagaAATTGGTCACTCCAAATTCCCttttta -
3’; 
sh-TERT B 5’-
gatccccCGGTGTACGCCGAGACCAATTttcaagagaAATTGGTCTCGGCGTACACCGttttta -
3’.
Semi-quantitative RT-PCR
Total RNA was isolated from HeLa S3 cells using Easy-BLUE (Intron, Korea). cDNA was 
reverse-transcribed from 1 μg of total RNA using M-MLV Reverse-Transcriptase (Promega) 
and used for semi-quantitative RT-PCR. 
The following primers were used: 
TERT F: 5'-CGG AAG AGT GTC TGG AGC AA-3’
TERT R: 5’-GGA TGA AGC GGA GTC TGG A-3’
TERC F: 5'-TCT AAC CCT AAC TGA GAA GGG CGT AG-3’
TERC R: 5'-GTT TGC TCT AGA ATG AAC GGT GGA AG-3’
dykerin F: 5'-ACA GGG TGA AGA GTT CTG GCA CAT-3’
dykerin R: 5'-TGA AGG TGA GGC TTC CCA ACT CAA-3’
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Cyclin D1 F: 5′-CAC ACG GAC TAC AGG GGA GT-3’
Cyclin D1 R: 5′-CAC AGG AGC TGG TGT TCC AT-3′
c-Myc F: 5’-AAT GAA AAG GCC CCC AAG GTA GTT ATC C-3’
c-Myc R: 5’-GTC GTT TCC GCA ACA AGT CCT CTT C-3’
GAPDH F: 5'-CTC AGA CAC CAT GGG GAA GGT GA-3’
GAPDH R: 5'-ATG ATC TTG AGG CTG TTG TCA TA -3’
Immunofluorescence and Fluorescence in situ hybridization (FISH)
Cells grown on cover slips were fixed with 4% paraformadehyde in PBS for 10 min and 
permeabilized in PBS containing 0.5% Triton X-100 for 10 min. Afterwards, cells were 
blocked in PBG (PBS containing 0.5% BSA,and 0.2% cold fish gelatin) for 10 min. Cells 
were incubated for 16 hr in PBG at 4°C with the following antibodies: anti-Coilin (abcam), 
anti-TERT (500ng/mL, Rockland)), anti-nucleolin(SantaCruz). Coverslips were washed 3 
times with PBG for 5 min each followed by incubation with Alexa Fluor 488 goat anti-rabbit 
immunoglobulin, Alexa Fluor 350 goat anti-mouse and Alexa Fluor 568 goat anti-mouse 
immunoglobulin (Molecular Probes) for 1 hr in PBG at room temperature. Finally, cover slips 
were washed 3 times with PBG for 5 min each and mounted using VectaShield (DAPI 
containing, Vector Labs) medium. 
For PNA-FISH, Cells grown on cover slips were fixed with 4% paraformadehyde in PBS for 
10 min and permeabilized in PBS containing 0.5% Triton X-100 for 10 min. Afterwards, cells 
were blocked in PBG (PBS containing 0.5% BSA,and 0.2% cold fish gelatin) for 10 min. 
Cells were incubated for 16 hr in PBG at 4°C with primary anti-bodies. After PBS washes, 
coverslips were incubated with alexa 488 secondary antibody raised against mouse or rabbit 
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for 45 min and washed in PBS. At this point, coverslips were fixed with 4% paraformaldehyde 
for 10 min at RT; washed extensively in PBS; dehydrated consecutively in 70%, 90% , and 
100% ethanol for 5 min each; and allowed to dry completely. Hybridization solution (70% 
formamide, 1mg/ml blocking reagent [Roche], 10Mm Tris-HCl, pH 7.2), containing the 
peptide nucleic acid(PNA) probe fluorescein isothiocyanate (FITC)-OO-(CCCTAA)3(Applied 
Biosystems), was added to each coverslip, and the cells were denatured by heating for 10 min 
at 82˚Ċ on a heat block. After 12-14 hr incubation at RT in the dark, cells were washed twice 
with washing solution (70% formamide, 10mm Tris-HCl, pH7.2) and twice in PBS. DNA was 
counterstained with DAPI (4’,6-diamidino-2-phenylindole) and the images were analyzed by 
Confocal analyses.
Double thymidine block of HeLa S3 cells 
HeLa S3 cells were grown in Dulbecco’s modified Eagle’s medium (Hyclone) containing 10% 
fetal bovine serum (Hyclone). Cells in the logarithmic growth phase were incubated in 
medium containing 2 mM thymidine (Sigma). After 19 h, cells were washed twice with PBS 
and grown in regular medium for 9 h before a second incubation with 2 mM thymidine for 17 
h. Cells released from the second thymidine block were collected at the indicated time.
Chromatin Immunoprecipitation assays
For in vivo ChIP assays, Hela S3 cells were washed twice in cold PBS and immediately cross-
linked with 1% formaldehyde for 30 min at room temperature. Formaldehyde was quenched 
by adding glycine (final 0.125 M concentration). Then cells were homogenized, and processed 
in ChIP-lysis buffer (50 mM Tris-HCl (pH 8.0), 1% SDS, 10mM EDTA) containing proteinase 
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inhibitors and further incubated on ice for 15 min. Cell lysates were sonicated to obtain 
chromatin fragments with an average size of 600 bp, and centrifugated (13,000 rpm, 20 min). 
Supernatants were removed, diluted with ChIP-dilution buffer (0.01% SDS, 1.1% TritonX-100, 
1.2mM EDTA, 16.7mM Tris-HCl(pH8.0), 150mL NaCl, proteinase inhibitor cocktails) and 
precleared with protein A sepharose bead (GE Healthcare) for 2 hr at 4 °C. Supernatant from 
precleared lysates was immunoprecipitated with Flag M2 agarose bead (sigma) overnight at 
4 °C and pulled down by centrifugation (9,000 rpm, 1min). Immunoprecipitates were further 
washed serially with low salt wash buffer( 0.1% SDS, 1% TritonX-100, 2 mM EDTA, 20 mM 
Tris-HCl (pH8.1), 150 mM NaCl ), high salt (0.1% SDS, 1% TritonX-100, 2 mM EDTA, 20 
mM Tris-HCl (pH8.1), 500 mM NaCl), LiCl wash buffer (10 mM Tris-HCl (pH 8.0), 1 mM 
EDTA, 250 mM LiCl, 1% NP40, 1% deoxycholate) and TE buffer, and eluted with freshly 
prepared elution buffer (1% SDS, 0.1 M NaHCO3). Finally, immunoprecipitates cross-linked 
were reversed by incubation at 65 °C overnight and treated with RNase A and proteinase K to 
extract DNA. The isolated DNAs were analysed by semiquantitative PCR. 
The primers used were the following: 
Cyclin D1-TBE-F: 5’- CGCTC CCATT CTCTG CCGGG-3’  
Cyclin D1-TBE-R: 5’- CCGCG CTCCC TCGCG CTCTT-3’
Cyclin D1-3’UTR-F: 5’- CAAGA GAAGA TTACC GCCCG AG-3’
Cyclin D1-3’UTR-R: 5’- TCCCC AGCCT TTTTG ACACC-3’
c-Myc-TBE1-F: 5’- CGTCT AGCAC CTTTG ATTTC TCCC-3’
c-Myc-TBE1-R: 5’-CTCTG CCAGT CTGTA CCCCA CCGT-3’
c-Myc-3’UTR-F: 5’-CTAAT GTATC ACAAA GTCCT TTA-3’
c-Myc-3’UTR-R: 5’-GTGAT CTGCT CTGTT AGCTT TTGA-3’
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Peptide identification using LC-MS/MS 
Nano LC–MS/MS analysis was performed with a nano HPLC system (Agilent,Wilmington, 
DE). The nano chip column (Agilent,Wilmington, DE, 150 mm × 0.075 mm) was used for 
peptide separation. The mobile phase A for LC separation was 0.1% formic acid in deionized 
water and the mobile phase B was 0.1% formic acid in acetonitrile. The chromatography 
gradient was designed for a linear increase from 5% B to 30 B in 25 min, 40% B to 60% B in 
5 min, 90% B in 10 min, and 5% B in 15 min. The flow rate was maintained at 300 nL/min. 
Product ion spectra were collected in the information-dependent acquisition (IDA) mode and 
were analyzed by Agilent 6530 Accurate-Mass Q-TOF using continuous cycles of one full 
scan TOF MS from 200-1500 m/z (1.0 s) plus three product ion scans from 50-1800 m/z (1.5 s 
each). Precursor m/z values were selected starting with the most intense ion, using a selection 
quadrupole resolution of 3 Da. The rolling collision energy feature was used, which 
determines collision energy based on the precursor value and charge state. The dynamic 
exclusion time for precursor ion m/z values was 60 s.
Fluorescence-activated Cell sorter(FACS) Analysis
Hele S3 cells were washed with ice-cold PBS and fixed overnight at 4 °C in ice-cold serially 
diluted 70% ethanol. The fixed cells were resuspended in PBS containing RNase A (200μg/ml) 
and propidium iodide(50μg/ml) and incubated in the dark for 30 min at 37 °C. Cell cycle 
progression was monitored by flow cytometry using a FACScan flow cytometer (BD 
Biosciences).
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4. Results
4.1 Identification of Nol1 as a TERT-interacting factor
hTERT has been known to be involved in cellular proliferation and cancer development 
through interacting with other proteins. We hoped to find proteins that interact with hTERT,
and expressed Flag-tagged hTERT protein in HEK293 cells and isolated hTERT complexes by 
using large scale affinity purification. Proteins co-purified with Flag-hTERT were identified 
by nano-liquid chromatography-tandem mass spectrometry (nano LC-MS/MS). Among the 
known telomerase components, TCAB1 and nucleolin were enriched in the hTERT complexes 
(Figure 1). In addition, analysis of a band migrating with an approximate relative molecular 
mass of 120 kDa identified NOL1, a highly conserved, nucleolar-specific, RNA-binding 
protein (Ochs et al., 1988; Jhiang et al., 1990). Since the NOL1 protein was detected in 
proliferating tissues but not in normal resting cells, NOL1 has been implicated as a tumor cell 
marker. Thus, we wanted to investigate the role of NOL1 in telomerase function.
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Figure 1. Identification of NOL1 as a TERC-interacting protein. Lysates from HEK293
cells expressing Flag-hTERT were immunoprecipitated with anti-Flag antibody and assayed 
for protein binding by Coomassie staining of SDS-PAGE gel. Binding proteins were identified 
by nano LC-MS/MS. Molecular size markers are shown in kilodaltons. Seventeen unique 
peptides for NOL1 identified from mass spectrometry are shown. 
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4.2. NOL1 interacts with TERT in vivo.
Since NOL1 was detected in proliferating tissues but not in normal resting cells, it has been 
implicated as a tumor cell marker. hTERT is also activated in many cancer cells but not in 
normal somatic cells. Thus, we wanted to investigate the role of NOL1 in telomerase function.
To determine whether hTERT and NOL1 associate in vivo, HEK293 cells were co-transfected 
with Flag-hTERT and NOL1-V5 expression vectors and subjected to immunoprecipitation. 
Co-immunoprecipitation with anti-flag antibody reveals Nol1 association with TERT, bringing 
down NOL1-V5 (Fig. 1a). Reciprocal immunoprecipitation showed that Flag-hTERT was 
detected in anti-V5 immunoprecipitates, indicating that hTERT associates with NOL1 in 
mammalian cells. Interestingly, the interaction between Flag-hTERT and NOL1-V5 was 
disrupted by RNase A treatment, which degraded TERC. Endogenous NOL1 was specifically 
bound to endogenous hTERT, and this association was also disrupted by RNase A treatment 
(Fig. 1b), suggesting that NOL1 associates with hTERT via TERC binding in vivo. These 
findings were further verified by immunoprecipitation experiments with U2OS cells, which 
lack endogenous hTERT and TERC28. Flag-hTERT did not interact with NOL1-V5 due to a 
lack of TERC (Fig. 1c). Taken together, these results suggest that NOL1 associates with 
hTERT via TERC in vivo.
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Figure 2. NOL1 interacts with TERT via TERC in vivo (a) HeLa S3 cells expressing Flag-
hTERT and NOL1-V5 were subjected to immunoprecipitation (IP) with anti-Flag and anti-V5 
antibodies, followed by immunoblotting with anti-V5 and anti-Flag antibodies. The extracts 
were treated with 0.1 mg/ml RNase A during immunoprecipitation to degrade TERC. (b) HeLa 
S3 cells were subjected to IP with anti-hTERT antibody, followed by immunoblotting with 
anti-NOL1 antibody. IgG was used as a negative control. (c) Telomerase-negative U2OS cells 
expressing Flag-hTERT and NOL1-V5 were subjected to IP with anti-Flag antibody, followed 
by immunoblotting with anti-V5 antibody.
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4.3 Domain mapping of TERT and Nol1 for their interaction
hTERT has four functional domains. The N-terminal domain(TEN) is involved in telomerase 
recruitment to telomeres and telomere synthesis. The TERT RNA binding domain(TRBD)
contains several RNA binding sequences required for TERC binding. The reverse transcriptase 
domain is important for its catalytic activity of the enzyme. The CTE domain plays a role in 
protein-protein interaction and telomerase localization.
Our data has shown that hTERT associates with NOL1. To better characterize this interaction, 
we mapped the domain in TERT that mediates the interaction with NOL1. To determine the 
domain in hTERT that is responsible for NOL1 interaction, we assessed binding of NOL1-V5 
by immunoprecipitating a series of deletion fragments of hTERT (Fig. 3a). NOL1-V5 was 
immunoprecipitated only by the hTERT fragments containing amino acid residues 1-589 (Fig. 
3b). Since this region contains the TERC-binding domain, we examined whether this domain 
is essential for NOL1 binding to hTERT. The results showed that removing the TERC-binding 
domain on hTERT abolished NOL1 binding (Fig. 3c,d), further supporting that the association 
of NOL1 with hTERT is mediated by TERC. To investigate the domain of NOL1 that is 
required for TERC binding, we generated deletion constructs lacking a coiled-coil domain or a 
putative rRNA methyltransferase domain29,30 (Fig. 3e). HEK293 cells were co-trasnfected with 
Flag-hTERT and a deletion construct of NOL1-v5 and subjected to immunoprecipitation. 
Flag-hTERT immunoprecipitated NOL1 fragments contaning amino acid residues 380-583 
(Fig. 3f), indicating that the putative rRNA methyltransferase domain is essential for hTERT 
binding.
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Figure 3. Identification of the domains in NOL1 and hTERT that are required for their 
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interaction. (a) Schematic representation of the region of hTERT involved in NOL1 binding. 
TRBD, TERC-binding domain. (b) Lysates from HeLa S3 cells expressing the various Flag-
hTERT domains and NOL1-V5 were immunoprecipitated with anti-Flag antibody, followed 
by immunoblotting with anti-NOL1 antibody. The Flag-TERT domains were indicated by 
arrows. The asterisks mark the positions of nonspecific immunoglobulin chains. (c) Schematic 
representation of mutant construct of hTERT in which the TRBD was deleted (ΔTRBD). (d) 
Removing the TRBD on hTERT abolishes NOL1 association. Lysates from HeLa S3 cells 
expressing either Flag-hTERT or Flag-ΔTRBD were immunoprecipitated with anti-Flag 
antibody, followed by immunoblotting with anti-V5 antibody. (e) Schematic representation of 
the region of NOL1 involved in hTERT binding. The approximate positions of nuclear 
localization signal (NLS), coiled-coil domain, and putative rRNA methyltransferase (MTase) 
motif are indicated (f) Lysates from HeLa S3 cells expressing the various NOL1-V5 domains 
and Flag-TERT were immunoprecipitated with anti-Flag antibody, followed by 
immunoblotting with anti-V5 antibody. The NOL1-V5 domains immunoprecipitated with 
Flag-hTERT were indicated by arrows. The asterisks mark the positions of nonspecific 
immunoglobulin chains.
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4.4 NOL1 associates with catalytically active telomerase but does not affect telomerase 
enzymatic activity.
Since NOL1 associates with hTERT via TERC binding, it is possible that NOL1 may be a 
telomerase holoenzyme subunit. To address this question, HEK293 cells were co-transfected 
with NOL1-V5 and either Flag-hTERT or Flag-TCAB1 or Flag-dyskerin and subjected to 
immunoprecipitation. The results showed that NOL1-V5 was immunoprecipitated by Flag-
TCAB1 and Flag-dyskerin, as observed in Flag-hTERT (Figure 4a). We next examined 
whether NOL1 associates with catalytically active telomerase. HEK293 cells were transfected 
with Flag-NOL1 or other Flag-tagged telomerase components, subjected to 
immunoprecipitation with Flag-antibody, and analyzed for telomerase activity by TRAP assay. 
Immunoprecipitates of Flag-NOL1 contained telomerase activity (Figure 4b), as did those of 
Flag-hTERT, Flag-TCAB1, and Flag-dyskerin, suggesting that NOL1 is a component of 
catalytically active telomerase. 
To investigate whether NOL1 is involved in canonical telomerase function, the expression 
of endogenous NOL1 was stably depleted in HeLa S3 cells using short hairpin RNA (shRNA) 
produced from a retroviral vector. NOL1 depleted cells maintained the reduced levels of 
NOL1 throughout the duration of the experiments (see below). Knockdown of NOL1 did not 
affect the levels of telomerase components and shelterin proteins which are responsible for 
telomere protection and maintenece (Figure 4c and 4d). When NOL1 knockdown cells were 
analyzed for telomerase activity by TRAP assay, telomerase activity was not influenced by the 
expression levels of NOL1 (Figure 4e). Taken together, these data indicate that although 
NOL1 associates with catalytically active telomerase, it has no direct regulatory effect on 
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telomerase enzymatic activity.
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Figure 4. NOL1 associates with catalytically active telomerase. (a) Lysates from HeLa 
S3 cells expressing NOL1-V5, together with Flag-hTERT, Flag-TCAB1 or Flag-dyskerin were 
immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-V5 
antibody. (b) Lysates from HeLa S3 cells expressing Flag-NOL1, Flag-hTERT, Flag-TCAB1 
or Flag-dyskerin were immunoprecipitated with anti-Flag antibody and analyzed for 
telomerase activity by the TRAP assay. ITAS, internal telomerase assay standard. (c) HeLa S3 
cells expressing control shRNA (shControl) or NOL1 shRNAs (shNOL1-1 and shNOL1-2) 
were subjected to immunoblotting to measure the protein levels of telomerase components and 
quantitative RT-PCR to detect the mRNA levels of telomerase components and TERC. (d) 
HeLa S3 cells expressing shControl or shNOL1 were subjected to immunoblotting to measure 
the levels of shelterin proteins. (e) HeLa S3 cells expressing shControl or shNOL1 were 
analyzed for telomerase activity by the TRAP assay. ITAS, internal telomerase assay standard.
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4.5 NOL1 does not influence the subnuclear localization of telomerase.
Telomerase undergoes a highly elaborate, stepwise process of assembly and trafficking 
within the nucleus (Lee et al., 2014). Human telomerase containing TERC is targeted to cajay 
body by interacting with TCAB1 and recruited to teloemeres. If NOL1 is required for 
assembly and trafficking of active telomerase, we would expect that depletion of NOL1
impairs subnuclear localizations of the telomerase components. To test this hypothesis, we 
depleted NOL1 in HeLa S3 cells and performed indirect immunofluorescence staining to 
monitor the subnuclear localization of endogenous hTERT. Since telomerase synthesizes 
telomeres specifically during S phase (Lee et al., 2010; Tomlinson et al., 2006), HeLa S3 cells 
were synchronized at S phase using double thymidine blockade (Lee et al., 2010). In the 
control cells, we observed the majority of hTERT was found to localize to nucleoli 
(Supplemental Figure S1A and S1B). NOL1 depletion does not affect the nucleolar 
localization of hTERT. Telomerase has been shown to accumulate in Cajal bodies prior to 
telomere elongation (Venteicher et al., 2009; Venteicher and Artandi 2009). Thus, we 
investigated whether NOL1 depletion affects co-localization of hTERT with Cajal bodies 
during S phase. Dual indirect immunofluorescence staining with a coilin-specific antibody and 
hTERT antibody showed that cajal body localization of hTERT was not influenced by NOL1 
depletion.(Supplemental Figure S1C and S1D). These results indicate that NOL1 does not 
affect the intranuclear trafficking of hTERT.
Dysfunctional telomeres are known to express DNA-damage response factors including   
γH2AX and 53BP1, and the resulting telomere dysfunction-induced foci (TIFs) represent the 
foci of DNA-damage response factors that coincide with telomeres (Takai H et al., 2003; 
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d’Adda di Fagagna et al., 2003; Karlseder et al., 1999). To investigate whether NOL1 
depletion may induce telomere-damage pathway, the telomeric foci was examined with using 
telomeric-DNA containing PNA probe and either anti-γH2AX or anti-53BP1 in NOL1 
knockdown and control cell lines. Depletion of NOL1 did not induce telomere-damage foci in 
the nucleus compared with the control cells (Supplemental Figure S2A and S2B), indicating 
that NOL1 is not implicated in regulating the DNA-damage response at telomeres.
34
Supplemental Figure 1. Subcellular localization of hTERT is not affected by NOL1 
depletion. (a) Colocalization of hTERT(green), nucleolin(red) in S-phase synchronized Hela 
S3- shControl and shNOL1 cell lines. (b) quantified colocalization of hTERT/nucleolin (mean 
and s.d. of triplicate experiments; n≥150). (c) colocalization of hTERT and coilin(red). (d) 
quntifed colocalization of hTERT/coilin. (nucleolin as a specific marker for nucleoli; coilin as 
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a specific marker for cajal bodies; DNA stained with DAPI (blue); 4’,6’-diamidino-2-
phenylindole).
Supplemental Figure 2. NOL1 depletion does not induce TIF formation. (a)
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Colocalization of 53BP1(green) and PNA (telomere, red) in HeLa S3 shvector or sh NOL1 
cell lines. (b) Colocalization of ᵞH2AX(green) and PNA (telomere, red) in HeLa S3 shvector 
and shNOL1 cell lines.
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4.6 Nol1 activates transcription of cyclin D1.
NOL1 is a proliferation-associated nucleolar protein, which is highly expressed in the 
majority of human malignant tumors and proliferating cells (Ochs et al., 1988; Jhiang et al., 
1990). NOL1 is expressed in the early G1 phase and peaks in S phase, suggesting the 
possibility that NOL1 might be involved in cell cycle regulation (Fonagy et al., 1992; Fonagy 
et al., 1993; Gorczyca et al., 1992). Although the expression of NOL1 was shown to be 
induced rapidly following growth stimulation and produce tumors in the nude mice (Perlaky et 
al., 1992), the mechanisms by which NOL1 exerts these effects reamin poorly understood. To
provide the further insight into the cell cycle and proliferation-related effect of NOL1, we 
investigated the effect of NOL1 depletion on the expression of cell cycle-dependent and 
proliferation-controlling genes such as cyclin D1 and c-Myc (Musgrove et al., 2011; Sears, 
2004). Depletion of NOL1 resulted in a clear reduction in the expression of cyclin D1 as 
shown by immunoblot analysis. Similar to this data, we found that the level of cyclin D1 
mRNA was also decreased by NOL1 knockdown as demonstrated by RT-PCR experiments, 
suggesting that NOL1 regulates the expression of cyclin D1 gene at transcriptional level 
(Figure 5a). In contrast, the expression of c-Myc was not affected by NOL1 depletion, 
implying that the regulation by NOL1 is promoter specific. Several studies have suggested 
that hTERT has a non-telomeric function in the gene regulation. Since it has been reported that 
telomerase modulates Wnt/β-catenin signaling by serving as a transcriptional cofactor in Wnt 
target genes (Park et al., 2009), we examined whether TERT is implicated in NOL1- mediated 
transcriptional activation of Cyclin D1 gene. The effect of NOL1 depletion on the cyclin D1 
expression was evaluated in U2OS cells, which lack endogenous hTERT and TERC.
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Consistent with the data seen in Hela S3 cells (Figure 5a), similar results were obtained in 
U2OS cells (Figure 5b), suggesting that NOL1-dependent activation of cyclin D1 transcription 
occurs regardless of telomerase expression.
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Figure 5. hTERT stimulates transcription of cyclin D1 gene through the interaction 
with NOL1. (a) HeLa S3 and (b) U2OS cells expressing shControl or shNOL1 were subjected 
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to immunoblotting to measure the protein levels of cyclin D1 and c-Myc and quantitative RT-
PCR to detect the mRNA levels. (c) The structures of the promoter luciferase constructs 
containing various lengths of upstream fragments in cyclin D1 gene are shown on the left. The 
binding sites of known transcription factors are indicated. The results of the luciferase assay 
are shown on the right. HeLa S3 cells were transfected with the promoter luciferase constructs 
together with Flag-NOL1 or empty vector. The firefly luciferase activity was normalized 
against the Renilla luciferase activity. Error bars show the standard deviation from the mean of 
three independent experiments. (d) The effects of TCF transcriptional activity after NOL1 or 
hTERT overexpression. HeLa S3 cells were transfected with TOP-flesh or FOP-flesh 
luciferase reporter vectors together with Flag-NOL1, Flag-hTERT or both. The firefly 
luciferase activity was normalized against the Renilla luciferase activity. Error bars show the 
standard deviation from the mean of three independent experiments. (e-g) The luciferase assay 
in H1299 (e), MCF7 (f) and U2OS (g) cells transfected with -964 promoter luciferase reporter 
vector together with Flag-NOL1, Flag-hTERT or both.
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4.7 Telomerase stimulates transcription of cyclin D1 gene through the interaction with NOL1.
The cyclin D1 promoter contains several distinct transcription factor binding sites targeted by 
different signaling pathways40. To determine the NOL1 responsive element, Hela CCL2 cells 
were transfected with a series of cyclin D1 promoter deletion constructs in the presence of 
NOL1. Luciferase assay data showed that the cyclin D1 transcription was activated about 4-
fold by NOL1 overexpression compared to the vector control (Fig. 5c). The proximal 85-base 
region, which contains TCF binding site (TBE), is essential for activation of the cyclin D1 
promoter, indicating that the NOL1 occupies the TBE region in the cyclin D1 promoter.
We next confirmed the effect of NOL1 overexpression on TCF binding activity by 
transfecting NOL1 expression with either a TCF-sensitive luciferase reporter vector (TOP-
FLASH) or a TCF-insensitive control vector (FOP-FLASH) in HeLa CCL2 cells. The results 
showed that the ectopic expression of NOL1 upregulated TOP-Flash activity but not FOP-
Flash activity (Fig. 5d). Interestingly, ectopic expression of hTERT alone was also able to 
induce TOP-Flash activity, which was further enhanced by co-expression of NOL1. To verify 
these findings, telomerase-positive H1299 and MCF7 cells were transfected with the -964 
promoter-luciferase reporter vector together with Flag-NOL1 or Flag-hTERT or both.
Overexpression of either NOL1 or hTERT led to an increase in cyclin D1 promoter activity 
compared to the vector control (Fig. 5e,f). When both proteins were co-expressed, we 
observed an additive effect on cyclin D1 promoter activity. These results suggest that both 
NOL1 and hTERT are required for the cyclin D1gene transactivation. 
Although NOL1 stimulates transcription of cyclin D1 gene independently of hTERT, it is 
unclear whether hTERT alone is sufficient to activate cyclin D1 promoter activity without 
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NOL1 association. To test this possibility, we examined dependence of NOL1 in telomerase-
negative U2OS cells. As shown in Fig. 5g, cyclin D1 promoter activity was enhanced by 
NOL1 overexpression but not by hTERT overexpression. Moreover, the additive effect was 
not observed by co-expression of both proteins. Since hTERT cannot associate with NOL1 in 
the absence of TERC (Fig. 2c), these findings could result from a lack of TERC in U2OS cells.
Taken together, these data suggest that telomerase promotes transcription of cyclin D1 gene 
through the association with NOL1.
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4.8 NOL1 and hTERT associate with the cyclin D1 promoter at the TCF binding site.
As NOL1 and TERT activate the TCF region of the cyclin D1 promoter, we wished to
determine whether both NOL1 and hTERT are recruited to the TCF binding site of cyclin D1 
promoter. Thus, we carried out chromatin immunoprecipitation (ChIP) to investigate TBE 
occupancy of the cyclin D1 gene promoter. HeLa S3 cells expressing Flag-NOL1 (or empty 
vector) and hTERT shRNAs (or control shRNA) were cross-linked with formaldehyde, 
followed by immunoprecipitation with anti-Flag antibody. The immunoprecipitated chromatin 
was used as template to amplify the TBE in the cyclin D1 promoter. The primers used in PCR 
analysis was used for probing the presence of NOL1 and hTERT on the cyclin D1 promoter.
The results showed that Flag-antibody immunoprecipitated the TBE-containing fragment 
when Flag-NOL1 was overexpressed (Fig. 6a). This TBE signal was not influenced by 
depletion of endogenous hTERT, suggesting that NOL1 binds to the TBE independently of 
hTERT. No amplification was observed when the immunoprecipitated chromatin was used to 
amplify the 3’-untranslated region (3’-UTR) (Fig. 6a). Because transcriptional activation by 
NOL1 is promoter-specific, we examined whether NOL1 is recruited to the c-Myc promoter 
and found that the Flag-NOL1 ChIP signal was not detected at the TBE of the c-Myc promoter, 
suggesting that NOL1 is not involved in the regulation of c-Myc transcription (Fig. 6b). We 
next analyzed the effect of hTERT depletion on the cyclin D1 transcription by luciferase assay. 
In HeLa S3 cells expressing the empty vector, depletion of hTERT reduced cyclin D1 
promoter activity (Fig. 6c). However, in cells expressing Flag-NOL1, cyclin D1 promoter 
activity was hyperactivated by NOL1 overexpression, and which was not affected by depletion 
of hTERT, further supporting the idea that NOL1 activates the transcription of cyclin D1 
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independently of hTERT expression. 
As we confirmed that NOL1 is independent of hTERT to bind to the cyclin D1 promoter, we 
tested whether occupancy of the cyclin D1 promoter by hTERT depends on NOL1, HeLa S3 
cells expressing Flag-hTERT (or empty vector) and NOL1 shRNAs (or control shRNA) were 
subjected to ChIP. The results showed that Flag-hTERT associates with the TBE-containing 
fragment of the cyclin D1 promoter in cells expressing control shRNA (Fig. 6d). When 
endogenous NOL1 was depleted, the ability of Flag-hTERT to bind to the TBE fragment was 
abrogated. These results suggest that hTERT can be recruited to the cyclin D1 promoter 
through the interaction with NOL1. Intriguingly, consistent ChIP signal of Flag-hTERT was 
detected at the TBE fragment of the c-Myc promoter regardless of NOL1 expression,
supporting the previous idea that NOL1 is not involved in the c-Myc gene regulation (Fig. 6e). 
We also examined the effect of NOL1 depletion on the cyclin D1 transcription. As expected, 
cyclin D1 promoter activity was downregulated by NOL1 depletion in HeLa S3 cells, (Fig. 6f). 
Even in the presence of overexpression of hTERT, cyclin D1 promoter activity could not be
activated due to NOL1 depletion (Fig. 6f), suggesting that NOL1 is required for TERT to 
activate cyclin D1 transcription.
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Figure 6. NOL1 and hTERT associate with the cyclin D1 promoter at the TBE. (a, b) 
HeLa S3 cells were transfected with Flag-NOL1 (or empty vector) together with hTERT 
shRNA (or control shRNA), and ChIP analyses were performed using Flag-antibody. The 
recruitment of NOL1 to the cyclin D1 TBE (a) or c-Myc TBE (b) was quantified by gel-based 
PCR assay. The 3’-untranslated region (3’-UTR) was used as a negative control. (c) The 
luciferase assay in HeLa S3 cells transfected with Flag-NOL1 (or empty vector) together with 
hTERT shRNA (or control shRNA). The firefly luciferase activity was normalized against the 
Renilla luciferase activity. Error bars show the standard deviation from the mean of three 
independent experiments. (d, e) HeLa S3 cells were transfected with Flag-hTERT (or empty 
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vector) together with NOL1 shRNA (or control shRNA), and ChIP analyses were performed 
using Flag-antibody. The recruitment of NOL1 to the cyclin D1 TBE (d) or c-Myc TBE (e) 
was quantified by gel-based PCR assay. The 3’-untranslated region (3’-UTR) was used as a 
negative control. (f) The luciferase assay in HeLa S3 cells transfected with Flag-hTERT (or 
empty vector) together with NOL1 shRNA (or control shRNA). The firefly luciferase activity 
was normalized against the Renilla luciferase activity. Error bars show the standard deviation 
from the mean of three independent experiments.
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4.9 Depletion of NOL1 induces cell growth arrest.
Since cyclin D1 plays an important role in the cell cycle progression through G1 phase (Yu et 
al., 2001), we determined the effect of NOL1 depletion on cell growth. HeLa S3 cells were 
transduced with the retrovirus particles expressing the control shRNA or NOL1 shRNAs, and 
stable cell lines were established from separate transductions to monitor the population 
doubling (PD) levels at regular intervals. The control HeLa S3 cells grew normally and 
continued to divide throughout the duration of the experiments (Figure 7a). In contrast, the 
growth rates of two independent NOL1 knockdown cells (NOL1 shRNA-1 and NOL1 
shRNA-2) gradually slowed down and stopped dividing at ~45 PD and ~30 PD, respectively. 
To determine whether the growth arrest correlates with an altered cell cycle distribution, the 
control cells and NOL1 knockdown cells were subjected to flow cytometric analysis by 
propidium iodide staining. At early PD, NOL1 knockdown cells showed cell cycle arrest at G1 
phase compared with cells expressing control shRNA (Figure 7b). In addition, NOL1 
knockdown cells exhibited a significant increase in sub-G1 DNA content at late PD, a 
characteristic of apoptosis (Figure 7c). Thus, the growth arrest of NOL1-knockdown cells 
could result from an inhibition of G1/S transition and an increased rate of cell death. Moreover, 
NOL1 knockdown cells showed increased levels of Bax and caspase-3 and decreased levels of 
Bcl-2 (Figure 7d). Taken together, these data support the idea that a growth arrest phenotype 
resulting from NOL1 depletion could be due to suppression of cyclin D1 transcription.
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Figure 7. Depletion of NOL1 induces cell growth arrest. (a) Cell growth curves of HeLa 
S3 cells stably expressing control shRNA or NOL1 shRNAs. Cells were repeatedly transfected 
with KIP siRNAs at 3-day intervals for 15 days. HeLa S3 cells were infected with the 
retrovirus particles to establish stable cell lines. Stable cells were replated every 3-4 days to 
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maintain log-phase growth and calculate the growth rate, with day 0 representing the first day 
after puromycin selection. (b) Flow cytometric analysis of HeLa S3 cells stably expressing 
control shRNA or NOL1 shRNAs. Cells were stained with propidium iodide at early and late 
PDs, followed by FACS analysis. (c) The percentage of total cells in sub-G1 phase of the cell 
cycle is shown. (d) HeLa S3 cells stably expressing control shRNA or NOL1 shRNAs were 
analyzed by immunoblot to measure the protein levels of Bcl2, Bax and caspase-3.
Figure 8. Proposed model for the two fates of telomerase during the assembly, telomere 
extension and transcriptional activation. After transcription, a TERC molecule assembles 
with dyskerin and hTERT in the nucleolus. Upon association with NOL1, the telomerase-
NOL1 complex is recruited to the TBE of the cyclin D1 promoter and activates its 
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transcription. For telomere extension, telomerase associates with TCAB1 and is transported to 
Cajal bodies. Telomerase-containing Cajal bodies are loaded on telomeric chromatin to
elongate telomere repeats. Because both NOL1 and TCAB1 associate with telomerase through 
TERC binding, these two factors might compete for binding to telomerase in the nucleolus.
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5. Discussion
Various studies have shown that human telomerase is highly expressed in most maligmant 
tumors while it is hardly detectable in normal human somatic cells which have a limited 
proliferative lifespan and eventaully enter a nondividing state of replicative senescence13. 
Although ectopic expression of telomerase is sufficient to extend a lifespan, recent studies 
have suggested that the ability of telomerase to promote tumorigenesis requires additional 
activities that are independent of its role in telomere extension14,15. Here we identify NOL1 as 
a TERC-binding protein, which is found in association with catalytically active telomerase. 
Since NOL1 has no direct regulatory effect on the canonical function of telomerase including 
the assembly and trafficking of telomerase as well as its enzymatic activity, it is possible that 
NOL1 is involved in extra-telomeric function of telomerase. We discovered that NOL1 
activates transcription of cyclin D1 gene by binding to the TCF binding element(TBE) of 
cyclin D1 promoter. Moreover, Telomerase is also recruited to the cyclin D1 promoter through 
the interaction with NOL1, further enhancing transcription of cyclin D1 gene. These data 
suggest that NOL1 represents a new pathway by which telomerase activates cyclin D1 
transcription, thus bypassing cell cycle checkpoint signaling pathway and allowing cells keep 
proliferating.
In addition to its primary role in telomere elongation, it has been recently reported that 
telomerase has noncanonical functions in signaling pathways that influence human 
tumorigenesis18,19,22. Telomerase has been shown to bind to the NF-κB p65 subunit and 
localize to the promoters of a subset of NF-κB target genes22. Moreover, inhibition of 
telomerase reduced the expression of NF-κB-dependent genes, indicating that telomerase acts 
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as a transcriptional modulator of the NF-κB signaling cascade in cancer cells. Telomerase has 
also been found to act as a transcriptional modulator of Wnt/β-catenin signaling pathway
through the interaction with BRG1, leading to enhanced expression of Wnt target genes such 
as cyclin D1 and c-MYC19. Furthermore, overexpression of alternatively spliced variants that
lack telomerase activity stimulates cell proliferation by activating Wnt signaling42. However, 
an influence of hTERT as a transcriptional modulator on Wnt signaling has not been 
consistently reproduced20,21. The discrepancy in the effects of hTERT overexpression may be 
attributed to the different cell types and experimental conditions. Since Wnt signaling target 
genes are also regulated by other signaling pathways43, the mechanism by which hTERT 
enhances the expression of growth-promoting genes could not be solely dependent on Wnt 
signaling. In this work, we show that telomerase interacts with NOL1 and promotes 
transcription of cyclin D1 gene in the absence of Wnt or NF-κB signaling. Whereas NOL1 
alone is sufficient to bind to the cyclin D1 promoter and promote its transcription, hTERT is 
recruited to the cyclin D1 promoter through its interaction with NOL1, suggesting that 
telomerase activates cyclin D1 transcription in a NOL1-dependent manner. Although TERC is 
not required for telomerase-dependent transcriptional gene activation in Wnt/β-catenin 
signaling, it is essential for cyclin D1 activation by NOL1 and telomerase. Analysis of domain 
mapping revealed that TERC binding domain in hTERT is responsible for NOL1 binding. 
Furthermore, we found the direct NOL1 interaction with TERC, supporting that the 
association between NOL1 and hTERT is dependent on TERC. Thus, a functional interplay 
between NOL1 and telomerase modulates the prolonged expression of cyclin D1 gene which
is critical for the maintenance of cell proliferation. 
NOL1 is a proliferation-related nucleolar protein, which is highly expressed in most 
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malignant tumor cells but not in normal resting cells23,24. Since telomerase is initially 
assembled in the nucleolus31, the finding that NOL1 is a novel component of catalytically 
active telomerase suggests that the nucleolus could be the site where NOL1 associates with the 
telomerase holoenzyme. Based on our data, we propose a model for the two fates of 
telomerase during its initial assembly, telomere extension and transcriptional activation (Fig. 
8). The assembly of the active telomerase holoenzyme occurs in a highly elaborate, stepwise 
fashion31. After transcription, a TERC molecule assembles with a preformed dyskerin 
complex, and the subsequent assembly of TERC-dyskerin RNP with hTERT occurs 
specifically during the S phase in the nucleolus. For telomere extension, telomerase associates 
with TCAB1 and is transported to Cajal bodies10,34. Telomerase-containing Cajal bodies are 
loaded on telomeric chromatin to elongate telomere repeats. On the other hand, when NOL1 is 
recruited to the telomerase RNP in the nucleolus, the NOL1-telomerase complex binds to the 
cyclin D1 promoter at the TCF binding site. Since both TCAB1 and NOL1 associate with 
telomerase through the interaction with TERC, these two proteins might compete for binding 
to telomerase in the nucleolus. The outcome of this competition may likely determine which 
of the two fates of telomerase is favored. Although we cannot rule out the possibility that both 
proteins exist in the telomerase complex, it will be interesting to investigate what fractions of 
the telomerase RNP contain NOL1 or TCAB1.
NOL1 is known to be expressed early in the G1 phase and peaks during the S phase25-27. 
Thus, NOL1-dependent transcriptional activation of cyclin D1 gene may occur in a cell cycle-
dependent manner. When telomerase is up-regulated in cancer cells, it could interact with 
NOL1 and occupy the TCF binding element of the cyclin D1 promoter to further facilitate the
gene expression. Thus, NOL1 plays an important role in cell cycle progression through G1 
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phase and is implicated as a tumor cell marker. On the contrary, repressing the cyclin D1 
expression by NOL1 depletion prevents the tumor cells exit from G1 phase, reversing tumor 
characters. Consistent with this idea, depletion of NOL1 induced a growth arrest at G1 phase 
in telomerase-positive HeLa S3 cells. This growth arrest was accompanied by several features 
consistent with the induction of apoptosis, including a substantial increase in sub-G1 DNA 
content. NOL1 knockdown cells exhibited an increase in the levels of pro-apoptotic Bax and 
cleaved caspase-3 and a decrease in the level of anti-apoptotic Bcl2. Given the importance of 
both telomerase and NOL1 in cancer progression, the functional interaction of telomerase and 
NOL1 plays an important role in the control of cell cycle progression through transcriptional 
induction of the cyclin D1 gene. Overall, our results provide for a novel function of NOL1 as 
an important regulator of cell cycle and proliferation as well as insight into the noncanonical 
mechanism by which telomerase promotes cell proliferation and inhibits cell growth arrest.
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Chapter 2 
TINF2 mRNA degradation by HuR modulates 
telomere function
61
1. Abstract
Shortened telomeres and stabilization of ARF tumor suppressors are most characteristic 
properties during a replicative senescence. In primary cells, telomeres are gradually shortened 
via the incomplete DNA replication. At the same time, ARF tumor suppressors are controlled 
by post-transcriptional regulatory processes, notably mRNA turnover and translation. Such 
processes include RNA binding proteins (RBPs) that selectively control the expression of 
subsets of genes. HuR (human antigen R), which is a member of the elav/hu family, facilitates 
senescent process through stabilizing mRNA of the ARF tumor suppressor. However, the 
precise linkage between stabilization of ARF tumor suppressor by HuR and shorten telomeres 
during a replicative senescence is unknown. Here, we show that HuR represses TINF2 (TRF1-
Interacting Nuclear Factor 2) through its 3’UTR, and stabilized TINF2 plays a role as driving 
force to be shorten telomeres during a replicative senescence. We found that loss of HuR 
induces stabilization of TINF2 mRNA, and stabilized TINF2 induces progressive telomere 
shortening. Furthermore, facilitated telomere shortening by stabilized TINF2 occurs prior to 
cell cycle arrest by stabilization of the ARF tumor suppressor. Our results demonstrate that 
progressive telomere shortening are concomitant to stabilization of the ARF tumor suppressor 
under orchestration of HuR during a replicative senescence.
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2. Introduction
During cell division, eukaryotic telomeres gradually shorten due to the incomplete replication 
of linear chromosomes by DNA polymerase, which is known as the end-replication problem 
(Blackburn 2001; Bell and Dutta 2002). Compensation for telomere attrition by telomerase is 
essential to overcome the end replication problem in stem cells and in most of the cancer cells 
(Weinrich et al. 1997; Marcand et al. 2000; Collins 2006). Telomere structural maintenance is 
important for chromosome integrity and has been implicated in aging and cancer (Mitchell et 
al. 1999; Artandi and Attardi 2005; Blasco 2005; Artandi 2006; Deng et al. 2008). Telomeres 
are composed of duplex tandem TTAGGG repeats with 3′ single-stranded G overhang and 
shelterin, a six-subunit complex that is required for the end-protection of chromosome ends 
(de Lange 2005). Shelterin localizes to telomeres via the duplex tandem TTAGGG repeat 
binding proteins TRF1 and TRF2 containing a C-terminal myb DNA-binding domain and an 
internal TRFH (TRF2 homology) homodimerization domain. TINF2 directly interacts with 
TRF1 and TRF2, and it binds to TPP1 that in turn recruits the 3’ single-stranded overhang 
binding protein POT1 (de Lange 2009). Although human RAP1 binds to TRF2 at telomeres, 
recent reports have shown that human RAP1 is not involved in telomere protection role (Kabir 
et al. 2014).
TINF2, a central component linking between TRF1 and TRF2, connects TPP1/POT1 to 
TRF1/TRF2 and contributes to telomere length regulation (Kim et al. 1999; Kim et al. 2004; 
Ye and de Lange 2004; Ye et al. 2004; O'Connor et al. 2006; Abreu et al. 2010; Takai et al. 
2011; Frescas and de Lange 2014b). Depletion of TINF2 causes substantial telomere 
deprotection due to destabilization of the shelterin components and induction of telomere 
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dysfunction-induced foci (TIFs) (Yamada et al. 2002; Kim et al. 2004; Yang et al. 2011; 
Bhanot and Smith 2012). Interestingly, TINF2 has a critical role in high-order telomeric 
complex assembly (Ye et al. 2004; Kaminker et al. 2005; O'Connor et al. 2006; Kim et al. 
2008). Increased levels of TINF2 lead to slight telomere shortening, preventing telomerase 
from elongating telomeres due to closed-state telomere structure (Kim et al. 2004). Mutations 
in TINF2 have been related to genetic diseases with premature aging phenotypes and bone 
marrow failures such as dyskeratosis congenita, ataxia-pancytopenia, and aplastic anemia
(Savage et al. 2008b; Savage et al. 2008a; Tsangaris et al. 2008; Walne et al. 2008; Du et al. 
2009; Walne and Dokal 2009; Bessler et al. 2010; Sarper et al. 2010; Yamaguchi et al. 2010; 
Yang et al. 2011; Gleeson et al. 2012; Sasa et al. 2012; Fukuhara et al. 2013; Frescas and de 
Lange 2014a; Alder et al. 2015). 
Recently, extra-telomeric functions of TRF1, TRF2, RAP1, and TINF2 among six core 
telomere proteins have been reported (Martinez and Blasco 2011). In particular, TINF2 was 
shown to localize to mitochondria (Chen et al. 2012; Sullivan et al. 2012). Reduced TINF2 by 
RNAi knockdown induced a decrease of several metabolites in the glycolytic pathway and 
inhibited reactive oxygen species (ROS) production and increased mitochondrial ATP 
synthesis and oxygen consumption in cancer cells, suggesting a link between telomeric 
proteins and mitochondrial metabolic pathway. However, although TINF2 participates in 
metabolic regulation in cancer cells, mitochondrial function of TINF2 in senescent cells is still 
unclear.
RNA-binding proteins (RBPs) are known as post-transcriptional regulators of gene 
expression, acting primarily through 5′ and 3′ untranslated regions (UTRs) of gene (Dynan 
and Tjian 1985; Moore 2005; Keene 2007; Lunde et al. 2007; Simone and Keene 2013; 
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Gerstberger et al. 2014). The RBP HuR (human antigen R, a member of the elav/hu family) 
regulates of stability of numerous target mRNAs and modulates the translation of mRNAs 
(Hinman and Lou 2008). Although HuR is predominantly localized in nucleus, its post-
transcriptional actions are linked to its cytoplasmic localization and its interaction with target 
mRNAs (Hinman and Lou 2008; Kim and Gorospe 2008). Through RIP-ChIP (RBP 
immunoprecipitation and microarray analysis) analysis or PAR-CLIP (Photoactivatable -
Ribonucleoside-Enhanced Cross-linking and Immunoprecipitation) analysis, numerous 
functional mRNA targets directly bound to HuR were identified (Keene et al. 2006; Lebedeva 
et al. 2011). Moreover, AU-rich elements (AREs) and polypyrimidine motifs were identified 
with already known HuR binding motifs (UUUUUUU, UUUAUUU and UUUGUUU) within 
target mRNAs. Through its actions on target mRNAs, HuR has been implicated in various 
biological processes, including cell division, immune and stress responses, differentiation, and 
carcinogenesis (Wang et al. 2000a; Wang et al. 2000b; Dean et al. 2001; Wang et al. 2001; 
Figueroa et al. 2003; Gorospe 2003; Lopez de Silanes et al. 2003; Mazan-Mamczarz et al. 
2003; Saunus et al. 2008; Ghosh et al. 2009; Katsanou et al. 2009; Kim et al. 2009; 
Topisirovic et al. 2009; Yi et al. 2010; Durie et al. 2011; Paukku et al. 2012; Srikantan et al. 
2012; Durie et al. 2013; Kawagishi et al. 2013; Pang et al. 2013; Singh et al. 2013; Hashimoto 
et al. 2014; Liu et al. 2014; Diaz-Munoz et al. 2015; Kim et al. 2015). In particular, reduced 
levels of HuR are known to facilitate senescent process through stabilizing mRNA of the ARF 
tumor suppressor (Wang et al. 2001; Wang et al. 2003; Yi et al. 2010; Pang et al. 2013; 
Hashimoto et al. 2014). However, it remains unclear whether HuR-dependent senescent 
process is accompanied by telomere shortening, which is general phenomenon in senescent 
cells.  
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In this work, we demonstrate that HuR interacts with and destabilizes TINF2 mRNA 
through its 3’ UTR. We found that functional activity and protein level of HuR are decreased, 
and which stabilizes TINF2 mRNA in senescent cells. We also show that knockdown of HuR 
by expressing retroviral shRNA induces telomere dysfunction-induced foci (TIFs) and cellular 
senescence, which is accompanied by G1 arrest in cancer cells. Furthermore, enhanced levels 
of TINF2 by knockdown of HuR led to substantial telomere shortening. Taken together, 
progressive telomere shortening due to enhanced levels of TINF2 by reduced level of HuR 
facilitates a replicative senescence with stabilization of the ARF tumor suppressor, suggesting 
that HuR orchestrates functional linkage between stabilization of ARF tumor suppressor and 
telomere shortening during a replicative senescence.
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3. Materials and methods
Cell culture
Human cervical carcinoma HeLa S3 and HeLa CCL2 cells and human embryonic kidney 
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium containing 10% fetal 
bovine serum with 100 units/mL penicillin, and 100 μg/mL streptomycin in 5% CO2 at 37 °C. 
Human osteosarcoma U2OS cells were grown in McCoy’s modified medium with10% fetal 
bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin in 5% CO2 at 37 °C. 
Constructs 
Standard recombinant DNA techniques were used to construct the following plasmids: FLAG-
tagged HuR fragment in pLNCX2 plasmid (Clontech), GFP-TINF2 3’UTR chimeric 
fragments in pEGFP-C1 plasmid (Clontech). The expression vectors were transiently 
transfected using Lipofectamine 2000 reagent according to the manufacturer’s protocol 
(Invitrogen). 
Stable cell line generation using retroviral expressing vector. 
293T cultures were grown in DMEM/10% bovine growth serum/100 units/mL penicillin, and 
100 μg/mL streptomycin. Retroviruses were generated from 293T cells by cotransfecting 
plasmids encoding pGP (gag/pol; TAKARA), pE-ampho (env;TAKARA) and the retroviral 
shRNA plasmids by Lipofectamine 2000 (invitrogen). To generate stable cell lines, HeLa S3 
cells were transduced with shRNA constructs in the pSUPER.retro.puro vector (Oligoengine), 
selected with 1μg/ml puromycin (GIBCO) for 2 weeks. For shRNA vectors, hairpin sequences 
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were: 
shHuR-1: 5’-gatccccgtctgttcagcagcattggttcaagagaccaatgctgctgaacagacttttta-3’;
shHuR-2: 5’-gatcccctgtgaaagtgattcgtgatttcaagagaatcacgaatcactttcacattttta-3’
Semi-quantitative RT-PCR
Total RNA was isolated from HeLa S3 cells using Easy-BLUE (Intron, Korea). cDNA was 
reverse-transcribed from 1 μg of total RNA using M-MLV Reverse-Transcriptase (Promega) 
and used for semi-quantitative RT-PCR. For semi-quantitative PCR of mRNA following RNA-
immunoprecipitation, the eluted immunoprecipitates were incubated with proteinase K at 45°C 
for 1hr, and then directly used for reverse transcription using the M-MLV reverse transcriptase. 
The following primers were used: 
HuR F: 5'-CGC AGA GAT TCA GGT TCT CC-3’
HuR R: 5’-CCA AAC CCT TTG CAC TTG TT-3’
GFP F: 5'-TAA ACG GCC ACA AGT TCA GCG T-3’
GFP R: 5’-AAG TCG TGC TGC TTC ATG TGG T -3’
TRF1 F: 5'-GGC TGG ATG CTC GAT TTC CT-3’
TRF1 R: 5’-GCC GCT GCC TTC ATT AGA A-3’
TRF2 F: 5'-CAA GTT CTA CTT CCA CGA GGC G-3’
TRF2 R: 5’-GCG GAC TCA GAT TTC AAA GCC-3’
RAP1 F: 5'-GCC TTG TGG AAA GCG A-3’
RAP1 R: 5’-TCT GGA GTT CTC TTA TTC TGT-3’
POT1 F: 5'-TCC AGA TTC CAG CAT CAG A-3’
POT1 R: 5’-GCA TTC CAA CCA CGG ATA-3’
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TPP1 F: 5'-GCT CAA TGC TGT GCA TCT CT-3’
TPP1 R: 5’-TGA GGA AGG AGG AGA GGC TA-3’
TINF2 F: 5'-TGT GGA TTT GGC CTC G-3’
TINF2 R: 5’-GAG AAG AGG TGA TAG AGA CT-3’
TERT F: 5'-CGG AAG AGT GTC TGG AGC AA-3’
TERT R: 5’-GGA TGA AGC GGA GTC TGG A-3’
TERC F: 5'-TCT AAC CCT AAC TGA GAA GGG CGT AG-3’
TERC R: 5'-GTT TGC TCT AGA ATG AAC GGT GGA AG-3’
dykerin F: 5'-ACA GGG TGA AGA GTT CTG GCA CAT-3’
dykerin R: 5'-TGA AGG TGA GGC TTC CCA ACT CAA-3’
TCAB1 F: 5'-CCA GCT CTT CTG TGG CTT CAA C-3’
TCAB1 R: 5'-AGG CTA TGC AGG AGA TGA TGC C -3’
SRSF11 F: 5'-TCC AGA CTC AGC AGT TGT GGC A -3’
SRSF11 R: 5'-GCA TTA GCT GGT GCC AAC AGA G -3’
GAPDH F: 5'-CTC AGA CAC CAT GGG GAA GGT GA-3’
GAPDH R: 5'-ATG ATC TTG AGG CTG TTG TCA TA -3’
Immunoprecipitation and immunoblot. 
The following antibodies were used: anti-Flag (M2, Sigma), HuR (3A2, SantaCruz), GFP (B-2, 
SantaCruz), dyskerin (H-300, SantaCruz), TRF1 (C-19, SantaCruz), TRF2 (D1Y5D, Cell 
signaling), RAP1 (A300-306A, Bethyl laboratories), POT1 (ab21382, abcam), TPP1 (ab54685, 
abcam), TINF2 (ab136997, abcam), Lamin A/C (N-18, SantaCruz), p53 (FL-393, SantaCruz), 
p21 (C-19, SantaCruz), p16 (H-43, SantaCruz) and tubulin (TU-02, SantaCruz). For 
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immunoblotting, whole-cell lysates were prepared using NP-40 lysis buffer (0.5% NP-40, 
1.5mM MgCl2, 25mM HEPES-KOH (pH7.5), 150mM KCl, 10% glycerol, Phosphotase 
inhibitor cocktail (Roche) and Proteinase inhibitor cocktail (Roche)) for 15 min at 4°C, 
followed by centrifugation (16,000 x g, 10 min). Supernatant fractions were denatured with 
5X SDS sample buffer at 95°C for 7 min, fractionated by SDS–PAGE and transferred onto 
nitrocellulose membrane. For immunoblot blocking and antibody incubation, 5% non-fat dry 
milk in TBS-T (25mM Tris-HCl, pH 8.0, 125mM NaCl, 0.5% Tween-20) was used. And then, 
membranes were washed 3 times for 5 min each in TBS-T, incubated for 1 hr in peroxidase-
conjugated secondary antibody (1:10,000, Gendepot), washed 3 times for 5 min each in TBS-
T and developed with ECL (Santa Cruz) solution. 
For immunoprecipitation, the cells were lysed with NP-40 lysis buffer for 15 min at 4°C, 
followed by spinning at 16,000 x g for 10 min. The cell lysates were pre-cleared with either 
mouse or rabbit IgG (SantaCruz) for 30 min and 30 μl of protein A sepharose (GE Healthcare). 
After spinning down (9,000 r.p.m., 1 min), the supernatant was transferred into fresh tubes and 
incubated with antibodies at 4°C overnight. Subsequently, 40 μl of protein A sepharose was 
added and incubated for 1 h. Immunoprecipitates were washed with NP-40 lysis buffer, then 
eluted by boiling in loading buffer and analysed by immunoblotting. Primary antibodies were 
used at the following concentrations: Flag (sigma): 500 ng/mL; HuR (SantaCruz): 200 ng/mL; 
GFP (SantaCruz): 200 ng/mL; dyskerin (SantaCruz): 200 ng/mL; TRF1 (SantaCruz): 200 
ng/mL ; TRF1 (Cell signaling): 100 ng/mL; RAP1 (SantaCruz): 50 ng/mL; POT1 (abcam): 
400 ng/mL; TPP1 (abcam): 200 ng/mL; TINF2 (abcam): 400 ng/mL; Lamin A/C (SantaCruz): 
200 ng/mL; p53 (SantaCruz): 200 ng/mL; p21 (SantaCruz): 200 ng/mL; p16 (SantaCruz): 200 
ng/mL; α-tubulin (SantaCruz): 200 ng/mL.
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Immunofluorescence and Fluorescence in situ hybridization (FISH)
Cells grown on cover slips were fixed with 4% paraformadehyde in PBS for 10 min and 
permeabilized in PBS containing 0.5% Triton X-100 for 10 min. Afterwards, cells were 
blocked in PBG (PBS containing 0.5% BSA and 0.2% cold fish gelatin) for 10 min. Cells were 
incubated for 16 hr in PBG at 4°C with the following antibodies: anti-53BP1 (2μg/mL, sc-
22760, SantaCruz), anti-γH2AX (2μg/mL, 2577, Cell signaling). Coverslips were washed 3 
times with PBG for 5 min each followed by incubation with Alexa Fluor 488 goat anti-rabbit 
immunoglobulin and Alexa Fluor 568 goat anti-mouse immunoglobulin (Molecular Probes) 
for 1 hr in PBG at room temperature. Finally, cover slips were washed 3 times with PBG for 5 
min each and mounted using VectaShield (H-1200, DAPI containing, Vector Labs) medium. 
For PNA-FISH, Cells grown on cover slips were fixed with 4% paraformadehyde in PBS for 
10 min and permeabilized in PBS containing 0.5% Triton X-100 for 10 min. Afterwards, cells 
were blocked in PBG (PBS containing 0.5% BSA and 0.2% cold fish gelatin) for 10 min. Cells 
were incubated for 16 hr in PBG at 4°C with primary anti-bodies. After PBS washes, 
coverslips were incubated with alexa 456 secondary antibody raised against mouse or rabbit 
for 45 min and washed in PBS. At this point, coverslips were fixed with 4% paraformaldehyde 
for 10 min at RT; washed extensively in PBS; dehydrated consecutively in 70%, 90%, and 100% 
ethanol for 5 min each; and allowed to dry completely. Hybridization solution (70% 
formamide, 1mg/ml blocking reagent [Roche], 10Mm Tris-HCl, pH 7.2), containing the 
peptide nucleic acid(PNA) probe fluorescein isothiocyanate (FITC)-OO-(CCCTAA)3(Applied 
Biosystems), was added to each coverslip, and the cells were denatured by heating for 10 min 
at 82˚Ċ on a heat block. After 12-14 hr incubation at RT in the dark, cells were washed twice 
with washing solution (70% formamide, 10mm Tris-HCl, pH7.2) and twice in PBS. DNA was 
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counterstained with DAPI (4’,6-diamidino-2-phenylindole) and the images were analyzed by 
Confocal microscopy analysis.
Fluorescence-activated Cell Sorter (FACS) Analysis 
HeLa S3 cells were washed with ice-cold PBS and fixed for 30 min in ice-cold serially 
diluted 70% ethanol. The fixed cells were resuspended in PBS containing RNase A (200 μg/ml) 
and propidium iodide (50 μg/ml) and incubated in the dark for 30 min at room temperature. 
Cell cycle progression was monitored by flow cytometry using a FACScan flow cytometer 
(BD Biosciences).
Double thymidine block of HeLa S3 cells 
HeLa S3 cells were grown in Dulbecco’s modified Eagle’s medium (Hyclone) containing 10% 
fetal bovine serum (Hyclone). Cells in the logarithmic growth phase were incubated in 
medium containing 5 mM thymidine (Sigma). After 19 hrs, cells were washed twice with PBS 
and grown in regular medium for 9 hrs before a second incubation with 2 mM thymidine for 
18 hrs. Cells released from the second thymidine block were collected at 2 hr intervals.
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4. Results
4.1 HuR associates with TINF2 mRNA.
HuR contains three RNA recognition motifs (RRMs) for binding to 5′ and 3′ untranslated 
regions (UTRs) of target mRNAs (Keene 2007; Wang et al. 2011; Simone and Keene 2013; 
Wang et al. 2013). Ribonucleoprotein (RNP) associations comprising (Peng et al. 1998; 
Lebedeva et al. 2011) HuR and its target mRNAs are controlled by proliferative and damage 
signals. Given the functions of its target mRNAs, HuR has been implicated in processes such 
as cellular proliferation, cellular senescence and responses to DNA damage (Wang et al. 2000a; 
Wang et al. 2000b; Wang et al. 2001; Mazan-Mamczarz et al. 2003; Wang et al. 2003; Kim et 
al. 2010; Yi et al. 2010; Pang et al. 2013; Hashimoto et al. 2014; Lal et al. 2014). Thus, we 
suggested that HuR has functional relationship with shelterin components. To determine 
whether HuR associates with mRNA of shelterin components, we first performed cross-linked 
immunoprecipitation (CLIP)-PCR assays in HeLa S3 cells or U2-OS cells (Figure 1). After 
UV cross-linking, endogenous HuRs were immunprecipitated with HuR-specific antibody and 
eluted mRNAs were analyzed by the semi-quantitative reverse-transcription (RT)-PCR (Figure 
1). The results showed that endogenous HuR associates with mRNA of TINF2 only (Figure 
1A and B). We also investigated functional relationship between HuR and mRNA of 
telomerase holoenzyme components (TERT, TERC, dyskerin, TCAB1, SRSF11). We found 
that mRNA of telomerase holoenzyme components do not associate with HuR (Figure 1A). 
Moreover, in U2-OS cells, which are telomerase negative cells, our results showed that 
endogenous HuR associates with mRNA of TINF2 only (Figure 1B). Taken together, HuR 
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associates with mRNA of TINF2 in both telomerase positive- and negative cancer cells.
Figure. 1. HuR associates with TINF2 mRNA
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Figure. 1. HuR associates with TINF2 mRNA (A) HeLa S3 cell lysates were subjected to 
RNP IP followed by RT–PCR analysis to measure the enrichment of shelterin mRNAs in HuR 
IP compared with control IgG IP. Graphical representation of the relative levels of shelterin 
mRNAs in HuR IP normalized against IgG IP. The mRNA levels were quantified with the 
average and standard deviation from three independent experiments. (B) U2-OS cell lysates 
were subjected to RNP IP followed by RT–PCR analysis to measure the enrichment of 
shelterin mRNAs in HuR IP compared with control IgG IP. Graphical representation of the 
relative levels of shelterin mRNAs in HuR IP normalized against IgG IP. The mRNA levels 
were quantified with the average and standard deviation from three independent experiments. 
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4.2. HuR does not associate with shelterin components and telomerase components in protein 
level.
HuR function in telomere is implicated in the regulation related to TERRA, which is a non-
coding RNA (Lopez de Silanes et al. 2010). Most of RNA regulation by HuR occurs at post-
transcriptional level. To exclude functional relationship between HuR and shelterin 
components/telomerase components in protein level, we performed co-immunoprecipitation 
(co-IP) assays. First, Flag-tagged shelterin components (TRF1, TRF2, RAP1, POT1, TPP1, 
TINF2) were transfected to HEK293cells and were immunoprecipitated with Flag M2-resin. 
The results show that shelterin components did not interact with HuR (Figure 2A). Moreover, 
in co-IP experiment with active telomerase components (TERT, dyskerin, TCAB1, SRSF11), 
they did not interact with HuR (Figure 2B).
Figure 2.HuR does not associate with shelterin components and telomerase components 
at protein level.
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Figure 2.HuR does not associate with shelterin components and telomerase components 
at protein level. (A) Lysates from HEK293 cells expressing Flag-TRF1, Flag-TRF2, Flag-
RAP1, Flag-POT1, Flag-TPP1 or Flag-TINF2 were immunoprecipitated with anti-Flag 
antibody, followed by immunoblotting with anti-Flag, anti-HuR and anti-α-tubulin antibodies. 
(B) Lysates from HEK293 cells expressing Flag-TERT, Flag-dyskerin, Flag-TCAB1 or Flag-
SRSF11 were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with 
anti-Flag, anti-HuR and anti-α-tubulin antibodies.
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4.3. HuR represses TINF2 expression at post-transcriptional level.
HuR is known as a modulator to regulate mature mRNA stability and translation. Thus, we 
suggested that HuR regulates TINF2 expression in vivo. To investigate whether HuR affects 
shelterin components at post-transcriptional level and translational level, we analyzed the 
expression level of shelterin components by overexpression of HuR. We first transduced 
retroviral pLNCX2-vector and pLNCX2-3xFlag-HuR to HeLa S3 cells (Figure 3). After 
incubation for 36hrs, cells were analyzed by Western blot assay with specific antibodies. The 
results showed that the overexpression of HuR reduced TINF2 protein level only (Figure 3A 
and B). Furthermore, we performed semi-quantitative RT-PCR assay to compare mRNA level 
of shelterin components by HuR. Consistent with the effect on protein level, overexpression of 
HuR reduced TINF2 mRNA only (Figure 3C and D). To further confirm that HuR negatively 
reduces TINF2 expression at post-transcriptional level, we transduced retroviral pLNCX2-
vector and pLNCX2-3xFlag-HuR to HeLa S3 cells and treated MG132 (proteasome inhibitor) 
for 4hrs before harvesting cells (Figure 3E and F). The results showed that HuR substantially 
decreased TINF2 expression at protein level and the reduced TINF2 levels were not recovered 
by treatment of MG132, indicating that HuR represses TINF2 expression at post-
transcriptional level.
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Figure 3. HuR represses TINF2 expression at post-transcriptional level.
79
Figure 3.HuR represses TINF2 expression at post-transcriptional level. (A) Forty-eight 
hours after transduction with a control plasmid expressing pLNCX2-vector or a plasmid 
overexpressing HuR as tagging protein 3xFlag-HuR in HeLa S3 cells, the levels of 
endogenous HuR, 3xFlag-HuR, TRF1(NE), TRF2, RAP1, POT1, TPP1, TINF2, Lamin A/C 
(NE) and α-tubulin were measured by the indicated antibodies. Graphical representation of the 
relative levels of shelterin proteins in overexpressed HuR normalized against a control in (C). 
The protein levels were quantified with the average and standard deviation from three 
independent experiments. NE; nuclear extracts. (B) Forty-eight hours after transduction with a 
control plasmid expressing pLNCX2-vector or a plasmid overexpressing HuR as tagging 
protein 3xFlag-HuR in HeLa S3 cells, HuR, TRF1, TRF2, RAP1, POT1, TPP1, TINF2 and 
GAPDH were measured by RT-PCR. Graphical representation of the relative levels of 
shelterin mRNA in overexpressed HuR normalized against a control in (D). The mRNA levels 
were quantified with the average and standard deviation from three independent experiments. 
(E) Forty-eight hours after transduction with a control plasmid expressing pLNCX2-vector or 
a plasmid overexpressing HuR as tagging protein 3xFlag-HuR in HeLa S3 cells, DMSO or 
10μM MG132 (proteasome inhibitor) were treated for 6hrs. The levels of endogenous HuR, 
3xFlag-HuR, TINF2 and α-tubulin were measured by the indicated antibodies. Graphical 
representation of the relative levels of TINF2 in overexpressed HuR normalized against a 
control in the absence (DMSO) or presence of MG132 in (F).
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4.4. HuR does not affect TINF2 protein stability.
HuR affects translational efficiency of mRNA and stability of proteins (eg. P53, XIAP, Wnt-
5a and HMGB1 etc.) (Mazan-Mamczarz et al. 2003; Leandersson et al. 2006; Durie et al. 2011; 
Dormoy-Raclet et al. 2013). To determine whether HuR affects protein stability of TINF2, we 
performed protein degradation assay with treatment of cycloheximide (protein de novo 
synthesis inhibitor). For knockdown of endogenous HuR, We first transduced retroviral 
shvector, shHuR-1 and shHuR-2 to HeLa S3 cells. After incubation of 36hrs, knockdown 
efficiency of HuR was analyzed by Western blot assay with specific HuR antibody (not shown 
in here). Harvested cells were subjected to Western blot assay with specific TINF2 antibody. 
The results showed that depletion of HuR did not affect protein stability of TINF2 (Figure 4A 
and B). Conversely, we transduced retroviral pLNCX2-vector and pLNCX2-3xFlag-HuR to 
HeLa S3 cells. The results showed that HuR represses TINF2 protein expression level, but 
does not affect protein stability of TINF2 (Figure 4C and D). Taken together, intrinsic TINF2 
protein itself is not regulated by HuR.
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Figure 4. HuR does not affect TINF2 protein stability. (A) Forty-eight hours after 
transduction with shvector or HuR shRNAs in HeLa S3 cells, cells were treated with 
cycloheximide (CHX, 10 mg/ml) and the levels of TINF2 and loading control α-tubulin were 
assessed by Western blot analysis. Graphical representation of the relative levels of TINF2 
proteins normalized against α-tubulin in (B). The protein levels were quantified with the 
average and standard deviation from three independent experiments. (C) Forty-eight hours 
after transduction with pLNCX2-vector or a plasmid overexpressing HuR as tagging protein 
3xFlag-HuR in HeLa S3 cells, cells were treated with cycloheximide (CHX, 10 mg/ml) and 
the levels of TINF2 and loading control α-tubulin were assessed by Western blot analysis. 
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Graphical representation of the relative levels of TINF2 proteins normalized against α-tubulin 
in (D). The protein levels were quantified with the average and standard deviation from three 
independent experiments.
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4.5. HuR regulates TINF2 expression through the TINF2 3’UTR.
To investigate whether HuR influences TINF2 expression by acting on the TINF2 3′UTR, a 
heterologous reporter construct expressing a chimeric RNA that spanned the GFP CR and the 
TINF2 3′UTR (Figure 5) was tested. As shown, overexpression of HuR reduced the 
expression level of GFP (Figure 5A) from the reporter chimeric plasmid pGFP(3′UTR), but 
not from pGFP. Graphical representation of the relative levels of GFP proteins normalized 
against α-tubulin was shown in Figure 5B. To further confirm the reduced expression of GFP-
3’UTR, we performed semi-quantitative RT-PCR with same experimental conditions. The 
results showed that overexpression of HuR reduced the expression of GFP-3’UTR at post-
transcriptional level (Figure 5A). Graphical representation of the relative levels of GFP mRNA 
normalized against GAPDH was shown in Figure 5C. Conversely, we tested whether HuR 
silencing influences TINF2 expression. We cotransfected shvector or shHuR with reporter 
chimeric plasmids to HeLa CCL2 cells. As shown in figure 5D-F, knockdown of HuR 
enhanced the expression of GFP-3’UTR (Figure 5D). Graphical representation of the relative 
levels of GFP proteins normalized against α-tubulin was shown in Figure 5E.  The enhanced 
expression of TINF2 was also confirmed by semi-quantitative RT-PCR with same 
experimental condition (Figure 5D). Graphical representation of the relative levels of GFP 
mRNA normalized against GAPDH was shown in Figure 4F. Taken together, we suggest that 
HuR represses TINF2 expression through 3’UTR of TINF2 mRNA.
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Figure. 5. HuR regulates TINF2 expression through the TINF2 3’UTR.
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Figure 5.HuR represses TINF2 expression through 3’UTR of TINF2 mRNA. (A) Plasmid 
pGFP-TINF2 3′UTR was constructed by attaching the entire TINF2 3′UTR after the GFP 
coding region. Forty-eight hours after co-transfecting pGFP or pGFP-3′UTR with pLNCX2-
vector or pLNCX2-3xFlag-HuR in HeLa CCL2 cells, the levels of reporter GFP protein, HuR, 
and loading control α-tubulin were measured by the indicated antibodies. Graphical 
representation of the relative levels of GFP proteins normalized against α-tubulin in (B). The 
protein levels were quantified with the average and standard deviation from three independent 
experiments. GFP and chimeric GFP-TINF2 3′UTR mRNAs were measured by RT-PCR. 
Graphical representation of the relative levels of GFP mRNA normalized against GAPDH in 
(C). The protein levels were quantified with the average and standard deviation from three 
independent experiments. (D) Plasmid pGFP-TINF2 3′UTR was constructed by attaching the 
entire TINF2 3′UTR after the GFP coding region. Forty-eight hours after co-transfecting pGFP 
or pGFP-3′UTR with shvector or shHuR in HeLa CCL2 cells, the levels of reporter GFP 
protein, HuR, and loading control α-tubulin were measured by the indicated antibodies. 
Graphical representation of the relative levels of GFP proteins normalized against α-tubulin in 
(E). The protein levels were quantified with the average and standard deviation from three 
independent experiments. GFP and chimeric GFP-TINF2 3′UTR mRNAs were measured by 
RT-PCR. Graphical representation of the relative levels of GFP mRNA normalized against 
GAPDH in (F). The protein levels were quantified with the average and standard deviation 
from three independent experiments.
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4.6. Identification of domains in TINF2 3’UTR that are associated with HuR.
As other HuR target mRNAs, TINF2 3′UTR is highly rich in As and Us (Figure 6A). We 
further investigated the association of HuR with the TINF2 mRNA by testing their association 
with HuR by RIP-PCR analysis. As binding was restricted to the 3′UTR (Figure 6B), we 
further subdivided it into four overlapping, ∼250-nt fragments and conjugated to GFP 
chimeric reporters (Figure 6B). Among them, HuR bound to the GFP Full and GFP B regions 
(Figure 6B and C). Validation of these findings by western blot showed that overexpression of 
HuR reduced the expression level of GFP in the GFP Full and GFP B from the reporter 
chimeric plasmid pGFP(3′UTR) (Figure 6D and E). Together, these findings suggested that 
HuR associated with the TINF2 3′UTR and reduced TINF2 levels by lowering the TINF2 
mRNA and by inhibiting its translation.
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Figure 6. Identification of domains in TINF2 3’UTR that are associated with HuR.
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Figure 6. Identification of domains in TINF2 3’UTR that are associated with HuR. (A) 
Sequence of the AU-rich TINF2 3′UTR. (B) Constructs were prepared to express chimeric 
RNAs spanning the GFP coding region and each of the four TINF2 3′UTR segments shown in 
(A). Forty-eight hours after transfection in HeLa CCL2 cells, binding of HuR to each chimeric 
RNA was tested by RNP-IP, followed by GFP mRNA detection by RT-PCR. Graphical 
representation of the relative levels of GFP mRNA in HuR IP normalized against IgG IP in (C). 
The mRNA levels were quantified with the average and standard deviation from three 
independent experiments. (D) Forty-eight hours after transfection in HeLa CCL2 cells, each 
chimeric GFP protein levels with overexpressed HuR was tested by Western blot analysis with 
the indicated antibodies. (E) Graphical representation of the relative levels of GFP protein in 
overexpressed HuR normalized against a control in (D). The mRNA levels were quantified 
with the average and standard deviation from three independent experiments.
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4.7. Loss of HuR induces cell growth retardation and represses TINF2 mRNA level.
A number of senescence-associated genes include As or Us-rich elements which are known 
targets to regulate mRNA turnover in their 3’ untranslated regions (UTRs), and various 
transcriptional regulators contribute to coordinate alterations in their mRNA stability (Keene 
2007; Simone and Keene 2013; Blackinton and Keene 2014). Alterations in mRNA stability 
are associated with RNA-binding proteins (RBPs) that enhance or reduce their stabilities. 
Among RBPs, HuR has been implicated in premature senescence process. Loss of HuR, 
indicating that HuR expression level and activity are reduced in senescent cells compared to 
younger cells in primary cells, induces replicative senescence through stabilization of tumor 
suppressor genes such as p21, p19ARF and p16INK4 in human fibroblasts or murine 
fibroblasts (Wang et al. 2001; Yi et al. 2010; Pang et al. 2013; Hashimoto et al. 2014). At the 
same time, deprotection of end chromosomes due to end-replication problem is a hallmark of 
aging and senescence (Cesare and Karlseder 2012; Cesare et al. 2013). Thus, shelterin, which 
is composed of six proteins associated with end-protection of chromosomes, also might be a 
target to be regulated by HuR during senescence, based on that HuR represses mRNA of 
TINF2 to regulate TINF2 level. To investigate whether HuR regulates expression of shelterin 
during senescence of primary cells, we first measured HuR levels in early- (PD5) and late-
passage (PD23) human caucasian foetal lung fibroblast IMR-90 cells. The standard for
passage of IMR-90 cells was based on the logarithmic growth curve and FACS analysis, 
referring previous observations that five TIFs in intermediate-state telomeres correlate with 
senescence induction via p53-dependent G1 arrest in human cells (Kaul et al. 2012) (Figure 
7A -D). In late-passage cells, HuR levels were reduced in protein level, not in mRNA level 
(Figure 7E and F). Concomitant with reduction of HuR level, TINF2 levels were enhanced
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in mRNA level (Figure 6A and B). During replicative senescence with activated p53 due to 
uncapped telomere, SIAH1 and TRF2 are upregulated and downregulated, respectively (Fujita 
et al. 2010). However, we could not observe significant reduction of TRF2 level. Moreover, 
overexpression of TINF2 stabilizes TRF1 and TRF2 level in protein level (Ye et al. 2004). 
Under our experimental conditions, we analyzed endogenous shelterin components at 
intermediate-state telomeres rather than uncapped telomeres, and could not observe significant 
change level of TRF1 and TRF2.
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Figure 7. Loss of HuR induces cell growth retardation and represses TINF2 mRNA level.
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Figure 7. Loss of HuR induces cell growth retardation and represses TINF2 mRNA level.
(A) Growth curve of long-term cultivation of IMR-90 cells. (B) Flow cytometric analysis of 
IMR-90 cells at early PDs and late PDs. Cells were stained with propidium iodide at early and 
late PDs, followed by FACS analysis. (C) IMR-90 cells were analysed by PNA-FISH for co-
localization of γ -H2AX or 53BP1 foci with telomeric sites marked by TTAGGG-specific 
FISH probe. Representative fluorescence images of nuclei showing a large number of γ -
H2AX or 53BP1 foci are shown as indicated. Immunofluorescence was used to detect γ -
H2AX or 53BP1 foci (green), and FISH was used to detect telomeric sites (red). DNA was 
stained with DAPI in the merged images. A subset of γ -H2AX or 53BP1 foci co-localized 
with TTAGGG probe is shown. (D) Quantification of TIFs shown in (C). The percentage of 
cells with >5 γ -H2AX or 53BP1 foci. For each condition, at least 100 cells were counted. (E) 
IMR-90 cells were collected at different PDs (Early PD, EP; Late PD, LP) and the levels of 
shelterin componenets (TRF1, TRF2, RAP1, POT1, TPP1 and TINF2), ARFs (p53, p21 and 
p16) and loading control α-tubulin and Lamin A/C were assessed by Western blot analysis. (F) 
Graphical representation of the relative levels of shelterin proteins normalized against α-
tubulin or Lamin A/C in (E). The protein levels were quantified with the average and standard 
deviation from three independent experiments. (G) IMR-90 cells were collected at different 
PDs (Early PD, EP; Late PD, LP) and the levels of shelterin componenets (TRF1, TRF2, 
RAP1, POT1, TPP1 and TINF2) and PCR loading control GAPDH were assessed by semi-
quantitative-RT PCR analysis. (H) Graphical representation of the relative levels of shelterin
mRNAs normalized against GAPDH in (G). The protein levels were quantified with the 
average and standard deviation from three independent experiments.
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4.8. HuR depletion upregulates TINF2 expression during cell growth retardation.
Increased levels of TINF2 lead to slight telomere shortening, preventing telomerase from 
elongating telomeres due to closed-state telomere structure (Kim et al. 2004). To determine 
whether enhanced TINF2 due to reduction of HuR contributes to the cell growth and the 
maintenance of telomeres, we stably expressed HuR shRNAs in HeLa S3 cells. During long-
term cultivation, HuR levels were stably knockdowned and endogenous TINF2 levels were 
upregulated (Figure 8E-H). Consistent with previous observations (Wang et al. 2000b; Wang 
et al. 2001; Mazan-Mamczarz et al. 2003), knockdown of HuR induced premature replicative 
senescence with p53-dependent G1 arrest through stabilization of ARFs such as p53, p21 and 
p16 (Figure 8A, B and E-F). Next, to investigate that HuR shRNAs induce dysfunction of 
telomeres during premature replicative senescence, we performed interphase-TIFs in HeLa S3 
HuR shRNA. The results showed that cells containing over five interphase-TIFs were 
significantly increased without chromosome fusions in shHuR-HeLa S3 cells compared with 
those in shvector-HeLa S3 cells, indicating that dysfunctional telomeres are induced at 
intermediate-state telomeres due to the depletion of HuR (Figure 8C and D).
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Figure 8. HuR depletion upregulates TINF2 expression during cell growth retardation.
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Figure 8. HuR depletion upregulates TINF2 expression during cell growth retardation.
(A) Growth curve of long-term cultivation of shvector, shHuR-1 and shHuR-2 HeLa S3 cells. 
(B) Flow cytometric analysis of HeLa S3 cells at pre-senescent point. Cells were stained with 
propidium iodide, followed by FACS analysis. (C) HeLa S3 cells were analysed by PNA-
FISH for co-localization of γ -H2AX or 53BP1 foci with telomeric sites marked by TTAGGG-
specific FISH probe. Representative fluorescence images of nuclei showing a large number of 
γ -H2AX or 53BP1 foci are shown as indicated. Immunofluorescence was used to detect γ -
H2AX or 53BP1 foci (green), and FISH was used to detect telomeric sites (red). DNA was 
stained with DAPI in the merged images. A subset of γ -H2AX or 53BP1 foci co-localized 
with TTAGGG probe is shown. (D) Quantification of TIFs shown in (C). The percentage of 
cells with >5 γ -H2AX or 53BP1 foci. For each condition, at least 100 cells were counted. (E) 
shvector, shHuR-1 and shHuR-2 HeLa S3 cells were collected at pre-senescent point and the 
levels of shelterin componenets (TRF1, TRF2, RAP1, POT1, TPP1 and TINF2), ARFs (p53, 
p21 and p16) and loading control α-tubulin and Lamin A/C were assessed by Western blot 
analysis. (F) Graphical representation of the relative levels of shelterin proteins normalized 
against α-tubulin or Lamin A/C in (E). The protein levels were quantified with the average and 
standard deviation from three independent experiments. (G) shvector, shHuR-1 and shHuR-2 
HeLa S3 cells were collected at pre-senescent point and the levels of shelterin componenets 
(TRF1, TRF2, RAP1, POT1, TPP1 and TINF2) and PCR loading control GAPDH were 
assessed by semi-quantitative-RT PCR analysis. (H) Graphical representation of the relative 
levels of shelterin mRNAs normalized against GAPDH in (G). The protein levels were 
quantified with the average and standard deviation from three independent experiments.
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4.9. HuR depletion induces imtermediate-state telomere during senescence.
To address checkpoint activation in IMR-90 cells at pre-senescent point or G1 arrested HeLa 
S3 cells due to knockdown of HuR, we monitored DNA damage response (ATM-Ser1981 and 
CHK2-Thr68) and stabilization of ARFs (p53, p21 and p16) at point containing intermediate-
state telomeres. The results showed that depletion of HuR activated ATM via phosphorylation 
at Ser1981, not CHK2 via phosphorylation at Thr68, which is agreement with checkpoint 
activation to differential DDR from the intermediate-state telomeres, subsequently 
accumulated p53, p21and p16 (Cesare and Karlseder 2012; Cesare et al. 2013)(Figure 9A and 
B). 
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Figure 9. HuR depletion induces imtermediate-state telomere during senescence. (A) and 
(B) IMR-90 cells and shvector, shHuR-1 and shHuR-2 HeLa S3 cells were collected at early 
PDs and pre-senescent PDs and the level of checkpoint activation (ATM-Ser1981, ATR-
Ser428, CHK2-Thr68 and CHK1-Ser345) and loading control α-tubulin were assessed by 
Western blot analysis.
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5. Discussion
In this study, we discovered that HuR represses TINF2 expression through binding to its 
3’UTR in human fibroblasts and cervical adenocarcinoma cell line. Similar to TRF2-mediated 
telomere-signaling during replicative senescence (Cesare et al. 2013), intermediate-state 
telomeres were induced by enhanced TINF2 due to reduction of HuR level, suggesting that 
elevated TINF2 level promotes the higher-order complex with TRF1 and TRF2, and telomere 
shortening to induce intermediate-state telomeres from closed-state telomeres. Although HuR 
shRNA activates ATM-Ser1981, knockdown of HuR by shRNA in p53-competent cancer cells 
or senescent primary cells do not contribute to the G2/M checkpoint (no CHK2-Thr68 
phosphorylation). Thus, cells containing intermediate-state telomeres passed through cell 
division without G2/M checkpoint activation, supporting that telomere-dependent growth 
arrest is restricted to diploid G1 phase cells.
It is well known that the RBP HuR (human antigen R, a member of the elav/hu family) 
regulates the stability of numerous target mRNAs and modulates the translation of mRNAs 
(Hinman and Lou 2008). HuR contains three RNA recognition motifs (RRMs) for binding to 5′
and 3′ untranslated regions (UTRs) of target mRNAs (Keene 2007; Wang et al. 2011; Simone 
and Keene 2013; Wang et al. 2013). Given the functions of its target mRNAs, HuR has been 
implicated in processes such as cellular proliferation, cellular senescence, and responses to 
DNA damage. In particular, reduction of HuR level facilitates senescent process by stabilizing 
mRNA of the ARF tumor suppressor (Wang et al. 2001; Wang et al. 2003; Yi et al. 2010; Pang 
et al. 2013; Hashimoto et al. 2014). In this study, we found that knockdown of HuR stabilized 
TINF2 mRNA to facilitate the higher-order complex, followed by shorten telomeres having 
characteristics of intermediate-state telomeres which are implicated as the activator of 
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replicative senescence (Karlseder et al. 2002).  
TINF2 is involved in the stabilization of human shelterin and the protection of telomeres 
(Kim et al. 2004; Liu et al. 2004; Ye and de Lange 2004). Moreover, human TINF2 plays an 
important role in the regulation of telomere length in telomerase-positive cancer cells (Kim et 
al. 1999). TINF2 DC mutations, which do not affect the interaction of TINF2 with TRF1, 
TRF2 and TPP1 among shelterin-binding partners, induce telomere shortening via 
mechanisms that involve both telomerase-dependent and telomerase-independent pathways 
(Kocak et al. 2014). However, a role of TINF2 in primary cells has not been fully understood. 
In this work, during replicative senescence, we observed loss of HuR levels, consistent with 
previous observations that HuR levels are low in fibroblasts undergoing replicative senescence 
(Wang et al. 2001; Pang et al. 2013). Loss of HuR reduced senescence-associated gene 
expression such as cyclin A, cyclin B1 and c-fos (Wang et al. 2001). Moreover, lower level of 
HuR stabilized ARFs such as p53, p21 and p16 induced replicative senescence (Kawagishi et 
al. 2013). Here, we found that TINF2 levels were enhanced by reduction of HuR in primary 
fibroblasts approaching pre-senescene point, and elevated TINF2 facilitated telomere 
shortening in IMR-90 shHuR (Figure 7 and 8). Thus, HuR plays a critical role in replicative 
senescence through the stabilization of ARFs, the modulation of senescence-associated gene 
expression and TINF2-mediated telomere shortening, simultaneously. These results indicate 
that TINF2 contributes to replicative senescence process.
The uncapped state telomeres are the fusion-sensitive and capable of activating CHK2-Thr68 
phosphorylation, as observed in TRF2-deletion murine models (Celli and de Lange 2005). 
Previous studies have shown that severe knockdown of TRF2 induced canonical DDR 
signaling in TRF2 shRNA cells and during lifespan extension, indicating canonical DDR from 
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uncapped-state telomeres and telomere-fusion-dependent genomic instability (Cesare and 
Karlseder 2012; Cesare et al. 2013). However, mild knockdown of TRF2 induced the 
differential DDR from intermediate-state telomeres. Differential DDR from telomeres 
indicates ATM-Ser1981 phosphorylation and no CHK2-Thr68 phosphorylation, which are
characteristic properties to mimic DDR from replicative senescence. In this study, knockdown 
of HuR in cancer cells or reduced HuR in primary fibroblsts activates ATM-Ser1981 
phosphorylation, but not CHK2-Thr68 phosphorylation during long-term cultivation. 
Dysfunctional telomeres due to elevated TINF2 by reduction of HuR coincide with the 
intermediate-state telomeres from mild knockdown of TRF2. In addition, reduced HuR 
induced cell growth retardation and arrested cells at G1 phase through the absence of CHK2 
activation, consistent with previous observations (Cesare et al. 2013). Overall, these 
observations demonstrate that deprotection of telomeres due to enhanced TINF2 level by 
reduction of HuR are closely implicated in the induction of intermediate-state telomere and 
replicative senescence.
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7. Summary (Korean)
텔로머레이즈에 의한 세포 주기조절에서 NOL1 기
능 분석 및 HuR에 의한 텔로미어 결합단백질
TINF2 mRNA 분해 기작 연구
연세대학교 대학원
융합오믹스 의생명과학과
홍주영
인간의 텔로머레이즈는 염색체 말단의 telomeric DNA repeats (TTAGGG)을 합
성하는 ribonucleoprotein (RNP) complex이다. 정상 체세포에서의 텔로머레이즈
의 역할은 노화를 극복하고 수명을 연장하는 것으로 충분하지만, 종양 세포에서의
텔로머레이즈는 텔로미어를 연장하는 것 말고도 그 외의 다른 활성을 갖는 것으
로 알려져있다. 이 연구에서 우리는 NOL1(proliferation-associated nuclear 
antigen p120)이 TERC를 통해 catalically active 텔로머레이즈와 결합하는 것을
보여준다. 또한, 우리는 NOL1은 cyclin D1의 프로모터에 결합하여 전사를 활성화
시키는 것뿐 만 아니라, 텔로머레이즈 역시 NOL1과 결합함으로써 cyclin D1의
프로모터에 결합하고 전사를 활성화시키는 것을 보여준다. 이는 텔로머레이즈가
NOL1 의존적으로 cyclin D1의 전사를 조절한다는 것을 말해준다. 이 연구에서
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우리는 NOL1에 의해 텔로머레이즈가 암세포의 생존과 성장 유지에 있어서 중요
한 성장 촉진 유전자들의 발현을 강화시킨 다는 것을 보여준다. 따라서, NOL1과
텔로머레이즈의 상호작용을 통해 계속적으로 세포가 분열할 수 있게 함으로써, 텔
로머레이즈의 non-canonical 기능이 암화 과정에 중요하다는 것을 밝혀냈다.
짧은 텔로미어 길이와 ARF 암 억제 유전자들의 안정화는 노화과정에서 보이는
특징적인 속성이다. Primary 세포에서 텔로미어는 불완전 DNA 복제 기작으로 인해
점점 짧아지는 동시에, ARF 암 억제 유전자들은 mRNA turnover나 번역과 같은 전
사 후 조절과정을 통해 조절된다. 그러한 조절 과정은 목표 유전자의 발현을 선택
적으로 조절하는 RNA 결합 단백질이 작용하게 된다. 그 중, elav/hu family인 HuR
가 ARF 암 억제 유전자들의 mRNA를 안정화시킴으로써 노화 과정을 촉진시킨다. 
그러나, HuR에 의한 ARF 암 억제 유전자들의 안정화와 노화과정에서의 텔로미어
길이 단축에 대한 정확한 연관성은 아직 잘 연구되지 않았다. 여기서, 우리는 HuR
가 TINF2(TRF1-Interacting Nuclear Factor 2)의 3’UTR에 결합함으로써 발현을 억제
시킨다는 것을 발견하였다. HuR의 발현감소는 TINF2의 mRNA를 안정화시켜, 곧 텔
로미어 단축을 가속화시킨다. 또한, 가속화된 텔로미어 단축효과는 ARF 암 억제
유전자들의 안정화로 인한 세포 주기 차단 에 앞서 그 이전에 발생한다는 것을
밝혀냈다. 따라서, 우리의 연구는 HuR에 조절에 따라 ARF 암 억제 유전자의 안정
화와 점진적인 텔로미어의 길이 단축과정이 노화과정에 동시에 수반된다는 것을
밝혀냈다.
                                                                            
핵심이 되는 말; Telomerase, NOL1, Cell cycle, Cyclin D1, Telomere, TINF2, 
HuR
